

Laboratory Service Guide



Contents

1.0 INTRODUCTION	3
1.1 Overview	3
1.2 Gnosis Laboratories Policy On Impartiality	3
1.3 Laboratory's Policy On Confidentiality Of Patient Information	4
1.4 Location of the Gnosis Laboratories, address and contact information	5
1.5 Operation Hours of the Gnosis Laboratory	6
1.6 Type of Laboratory Services	7
2.0 GENERAL REQUIREMENTS	9
3.0 BLOOD SAMPLE COLLECTION	15
4.0 SPECIAL SPECIMEN COLLECTION PROCEDURES FOR BIOCHEMISTRY TESTS	24
4.1 24-HOUR URINE COLLECTION	24
4.2 24-HOUR URINE COLLECTION for CATECHOLAMINES	24
5.0 SPECIMEN COLLECTION FOR MICROBIOLOGY TEST	26
5.2 Urine Culture	26
5.3 Blood Culture	28
5.4 Nasal Swab	28
5.5 Genital Tract Swabs	29
5.6 Rectal Swabs	29
5.7 Pus Samples/ Wound Swabs	30
5.8 Abscess	30
5.9 Eye Swab	30
5.10 Throat Swab	31
5.11 Sputum Collection	31
6.0 SPECIAL PROCEDURES FOR HISTOPATHOLOGY AND CYTOLOGY TEST	31
6.1 Histopathology	31
6.2 Gynaecological Pap Smears (Pap Test)	32
Indication	32
7.0 SEMEN COLLECTION	33
8.0 CRITICAL LABORATORY VALUES	35
9.0 List of tests provided by Gnosis Laboratory Sdn Bhd	37

1.0 INTRODUCTION

1.1 Overview

Gnosis Laboratories (M) Sdn Bhd, a medical laboratory company which began operation in the year 2002, was jointly created by Lezen Reference Laboratories and local medical laboratory professionals. Gnosis Laboratories works with physicians, hospitals and other healthcare providers to help deliver better outcomes in patient care. We offer the following services:

- A broad range of routine laboratory tests
- Access to highly specialised clinical tests
- Occupational Health Services
- Functional Health Test
- Laboratory testing and management for hospitals
- Professional health services for employers, insurers and government agencies

Lezen Reference Laboratories (<http://www.lezen.com.tw>) is a well-known and respected company of Taiwanese nationality. Lezen Reference Laboratories was established in 1978 and has since grown to be a major medical reference laboratory for clinics, medical laboratories, hospitals and university research units. They received and performed approximately 5,000 patient cases a day, with numerous requests for routine and special testing. As a reference and research-led medical laboratory, Lezen Reference Laboratories always seeks collaboration with medical and academic institutions to be actively involved in research projects.

For Lezen Reference Laboratories, joint venture partnerships open up new market opportunities and access to Malaysian local market knowledge. For Gnosis Laboratories (M) Sdn Bhd, the benefits include gaining access to world-leading technologies and proven experience in delivering large-scale projects.

Service Quality

Gnosis Laboratories' core concern is always about providing accurate and time-efficient laboratory results to our medical partners. We demonstrate our commitment to continuous quality improvement through a series of interrelated quality control and quality assurance programs which evaluate our pre-analytical, analytical and post-analytical services. Among the programs are:

- Taiwan Accreditation Foundation (TAF), according to ISO 15189 standards
- College of American Pathologists (CAP) Proficiency Surveys
- Biorad, External Quality Assessment Scheme (EQAS) from California, USA
- The Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP)

1.2 Gnosis Laboratories Policy on Impartiality

Gnosis Laboratory Sdn Bhd is committed to delivering accurate and reliable diagnostic services. All personnel are expected to perform their duties with impartiality and objectivity, ensuring that results and decisions are based solely on scientific and clinical evidence.

1.3 Laboratory's Policy on Confidentiality of Patient Information

GENERAL POLICY

The Gnosis Laboratory will ensure the protection of its customers' proprietary rights and maintain confidential information about patients and other users of the laboratory.

Management of Information

In compliance with the *Personal Data Protection Act 2010*, the confidentiality of patient information will be maintained at all times.

- a) It is the laboratory's policy to protect all patients' personal information, including information that:
 - Is received, maintained or transmitted in ANY format
 - Relates to the patient's past, present, or future medical information,
 - Treatment, or payment for care.
 - Identifies the patient or could be used to identify the patient.
- b) Only authorized healthcare providers can access patients' health information in the Gnosis Laboratory Information System (GIMS)
- c) Once the report is successfully sent and acknowledged receipt by the requestor, it is considered the property of the requestor.
- d) Do not attempt to recycle the unused Laboratory report for any purposes

Release of information

- a) Patient results are only telephoned to the ordering clinician or authorised/designated employees within the originating clinic or healthcare facility.
- b) Patient results must only be faxed to designated fax numbers as provided by the clinician
- c) Electronic results sent via email are transmitted in an encrypted format to designated addresses
- d) Hard copy reports are placed in closed folders or envelopes before being sent to the originating clinic or ordering physician
- e) Sensitive results (where known, e.g., HIV reactive, Western Blot, etc) are handled with extra precaution, with results sent to the ordering physician in a sealed envelope if the ordering physician is still routinely receiving paper copies of results.

Exception in release of information.

The Private Healthcare Facilities and Services Act 1998 (Act 586) and its regulations, along with the MMC Code of Professional Conduct 2019, govern the release of patient information by private laboratories to the Ministry of Health (KKM), emphasizing patient consent and confidentiality, while also allowing for exceptions in specific circumstances. Exceptions include:

- a) **Notifiable Diseases:** Certain diseases are legally mandated to be reported to the *Ministry of Health (KKM)*, regardless of patient consent.
- b) **Court Orders:** A court order may compel the release of patient information for legal proceedings.
- c) **Specific Legislation:** Other laws may require the disclosure of certain health information to the MOH.
- d) **Public Health Interest:**
Public Health Emergencies: In situations of public health emergencies, such as outbreaks of infectious diseases (e.g. COVID), the *Ministry of Health (KKM)* may require access to patient information to effectively manage and control the situation.

As a general rule, if there is any uncertainty regarding the confidentiality of any patient's results, the The query should be referred to the Laboratory Quality Manager and/or Laboratory Director.

1.4 Location of the Gnosis Laboratories, address and contact information

The addresses and contact numbers of Laboratory Headquarters and Branch Laboratories are as below.

Website: gnosis-healthcare.com

PENINSULAR

Subang Jaya (Central Lab):

1-1 & 1-2, Jalan USJ 21/11, 47630 Subang Jaya, Selangor, Malaysia.

Tel: 603-5885 8501/ 8502/ 8503 Fax: 603-5885 8510 E-mail: hqlab@gnosis-healthcare.com

Klang:

38A, 1st Floor, Jalan Batu Unjur 1, Taman Bayu Perdana, 41200 Klang, Selangor.

Tel: +603-3311 5817 E-mail: klanglab@gnosis-healthcare.com

Ipoh:

Hospital Seri Botani, Level 1, Pathology Lab, No. 3, Dataran Botani 2, Bandar Seri Botani, 31350 Ipoh, Perak.

Tel: 605-226 2768 Fax: 605-226 2769 E-mail: ipohlab@gnosis-healthcare.com

Penang:

70-2-56A, D'Piazza Mall, Jalan Mahsuri, 11900 bayan Baru, Pulau Pinang.

Tel: 604-642 8771 E-mail: penanglab@gnosis-healthcare.com

Kulim:

9, Jalan Lunas, Taman Badlishah, Kelang Lama, 09000 Kulim, Kedah.

Tel: 04-4902315 E-mail: kulimlab@gnosis-healthcare.com

Johor Bharu:

10-A, Jalan Indah 1, Taman Bukit Indah, 81200 Skudai, Johor Bharu, Johor.

Tel: 607-2445177 Fax: 607-2445077 E-mail: jblab@gnosis-healthcare.com

Melaka:

No.9-1 (1st Floor), Jalan KL 3/15, Taman Kota Laksamana, Seksyen 3, 75200 Melaka.

Tel: 04-4902315 E-mail: melakalab@gnosis-healthcare.com

Seremban:

28-1, Jalan Rasah Prima 2, Pusat Komersial Rasah Prima, 70200 Seremban, Negeri Sembilan.

Tel: +606-6316 788 E-mail: serembanlab@gnosis-healthcare.com

Kuantan:

A9-A11, Mezzanine Floor, Jalan Dato Wong Ah Jang, 25100 Pahang.

Tel: 011-1653 7500 E-mail: kuantanlab@gnosis-healthcare.com

SABAH

Kota Kinabalu:

Lot A-1-1, First Floor, Block A, 88 MarketPlace, Jalan Pintas, 88300 Kota Kinabalu, Sabah.

Tel: 6088-212 525 E-mail: kklab@gnosis-healthcare.com

SARAWAK

Kuching:

No.33, Sublot 7, Lot 1108, Block 10, KCLD, Hock Hui Commercial Centre, Jalan Tun Ahmad Zaidi Adruce, 93250 Kuching.

Tel: 082-245996

E-mail: kuchingadmin@gnosis-healthcare.com

Sibu

No.14, Jalan Dr Wong Soon Kai, 96000 Sibu, Sarawak.

Tel: 084-332600 Fax: 084-346700

E-mail: sibuadmin@gnosis-healthcare.com

Miri:

Lot 292, Beautiful Jade centre, Jalan Bendahara, 98000 Miri.

Tel: 085-439068

E-mail: mirilab@gnosis-healthcare.com

Bintulu:

No.16, 1st Floor, Parkcity Commerce Square, Jln Tun Ahmad Zaidi, 97000 Bintulu, Sarawak.

Tel: +6086-317400

E-mail: bintululab@gnosis-healthcare.com

1.5 Operation Hours of the Gnosis Laboratory

The Subang Jaya HQ laboratory operates on a 24-hour basis. Specimen collection hours are as follows:

Day	Routine Hours	On-Call Hours
Monday to Friday	9:00 am to 5:30 pm	5:30 pm to 7.00 pm
Saturday	9:00 am to 1:00 pm	1:00 pm to 3:00 pm
Sunday	-	9:00 am to 3:00 pm
Public Holiday	Close	Subject to notification

The above hours apply exclusively to the Subang Jaya HQ. Please contact individual branch laboratories directly for their specific operating hours.

1.6 Type of Laboratory Services

Routine Tests

Gnosis Laboratories always seeks and employs state-of-the-art technology in providing the highest quality and reliable test results for our customers.

The routine tests that we are providing are:

- Clinical Chemistry
- Haematology
- Urinalysis
- Immunoassay
- Microbiology
- Histology
- Cytology

Our routine tests package is designed based on cost-effectiveness and its usefulness in helping physicians to assess and diagnose patients.

Refer to our Service Catalogue for details.

Specialized Tests

Together with our partners, we provide access to specialised clinical tests that range from early detection of cancer to diagnosing allergies, from measuring Growth Hormone, HBV DNA Viral Load to providing Functional Medicine Testing.

Among the specialised clinical laboratory tests are as follows:

- Anti-CCP
- Allergy Testing: Allergy AD40 (40 types of allergens)
- Tumour marker for lung: Cyfra 21-1, NSE, SCC Ag
- Tumour marker for stomach: CA 72-4
- Infertility testing: Anti-Mullerian Hormone (AMH)
- DNA Paternity Testing
- Prenatal Screening Test: Double Tests (Down's syndrome screen), First Trimester Down's Syndrome Screen, Second Trimester Quadruple test for Down's syndrome screen
- Herpes simplex virus (HSV 1 & 2) typing
- Human Papillomavirus (HPV) genotyping and Cervical Cancer screening
- HBV DNA Viral Load and Genotyping
- HCV RNA Viral Load and Genotyping
- HIV RNA Viral Load
- Chlamydia DNA Test
- Gonorrhoea DNA Test
- Mycobacterium Tuberculosis DNA Testing
- Ageing Hormone: IGF-1, DHEA-S, Insulin, C-peptide, Testosterone, Dihydrotestosterone, etc
- Protein electrophoresis, immunoglobulin electrophoresis, Hb electrophoresis, etc
- Heavy Metal toxicity: Mercury, Arsenic, Lead, etc
- Oncology Testing

Functional Health Tests

Gnosis Laboratories' dedication to innovation has led us to investigate a variety of new areas to expand our testing base, thereby providing healthcare providers with a comprehensive diagnostic menu to serve their patients. Gnosis Laboratories is looking at Functional medicine as a new approach to help physicians manage and prevent chronic disease that embodies the art and science of medicine. Functional Medicine integrates what we know about how the human body works with patient-centred, science-based care. Functional medicine addresses the causes of chronic disease, which are rooted in lifestyle choices, environmental exposures, and genetic influences.

Please refer to the Nutritional Medicine Assessment Service Catalogue for details.

Examination Offered by Laboratory

Please refer to the **Gnosis Service Catalogue** for the full range of examinations offered by the laboratory, including, as appropriate, information concerning samples required, primary sample volumes, special precautions, turnaround time, and price.

Please contact the lab servicing in your area for details of biological reference intervals and clinical decision values.



Complaint or Feedback

To continue to improve and provide better service, we need the valuable feedback and suggestions from you, as our valued customer.

If you have a complaint or feedback (positive /negative), please: -

1. Contact the Customer Service Centre, Marketer or Laboratory frontline staff. Operational Manager/Business Manager
2. The telephone numbers have been given for each branch in the list of branches above
3. Obtain feedback forms, which are available in all the branches.
4. Feedback can also be provided via GNOSIS LAB HOTLINE +6 (03) - 588-58501 or online on our website <https://gnosis-healthcare.com>
5. Verbal complaints may also be given to the staff at the counter in all the branches,
6. Acknowledgement and the complaint number will be given immediately
7. For all the other modes of feedback, acknowledgement will do within 48 hours (either verbally through a telephone call or email)
8. All complaints will be investigated, and a written reply will be given to the complainant as soon as the investigation is over.
9. If the complainant requires further clarification, to be provided in writing or a face-to-face meeting, a meeting will be arranged with the relevant parties to help resolve the matter and give closure to the complaint.

2.0 GENERAL REQUIREMENTS

2.1 Patient Preparation

Pre-instruction should be provided to the patient, such as fasting, special dietary consumption, or other requirements, before sample collection. In the event that the test requires self-collection of the sample, kindly provide specific instructions to the patient.

2.2 Patient Identification

- a) Each patient must be identified using active communication techniques. At least **two patient identifiers** (patient's name / Identification number (I.C. No/Passport number/MRN, etc) are needed before collecting the sample from the patient.
- b) The patient's identity is verified by asking the patients to identify themselves before collecting the samples.
- c) The sample tubes/containers shall be labelled with the identifiers in the presence of the patient at the time of collection.

2.3 Patient's Informed Consent

- a) Please provide a clear explanation to the patients about the laboratory tests and how they will be collected.
- b) For most routine laboratory procedures, consent can be inferred when the patient willingly submits to the sample collection procedure, for example, venipuncture.
- c) Where necessary, such as HIV testing, please obtain written informed consent
- d) Special procedures, including more invasive procedures or those with an increased risk of complications to the procedure, may need a more detailed explanation and, in some cases, recorded consent.
- e) If obtaining consent is not possible in emergencies, the laboratory may carry out necessary procedures, provided they are in the patient's best interest. Please Note in the Test Requisition Form.

2.4 Sample Collection

The samples should be properly collected in appropriate containers.

The containers must be labelled with at least two identifiers (i.e. name of patient and patient's I.C. number) and the name of the test requested.

The containers should be placed in biohazard plastic bags with the respective request forms stapled outside the bag.

2.5 Types of containers

Refer to the list of tests for the guidelines and recommendations.

2.5.1 Type of Vacutainer Tubes

Blood collection tube	Additives	Volume	Mix by inverting	Common Use
Yellow 	Serum Separator Tube (SST) Plain tube with gel	5 ml	Invert the tube gently 6-8 times after collection	Chemical Pathology: General chemistry, Tumour markers, Hormones, Special proteins, Anaemia profile, Protein electrophoresis, Microbiology: Immuno. serology and virology (other than molecular)
Red 	Plain tube without gel	7ml	Invert the tube gently 6-8 times after collection	Chemical Pathology: Rheumatoid Factor, Therapeutic drug monitoring (TDM) except Immunosuppressant Microbiology: Virology
Lavender 	EDTA (K2)	3ml	Note: Adequate sample volume is VERY IMPORTANT. Invert the tube gently 8-10 times after collection.	Chemical Pathology: ACTH (in ice), HbA1c, Ammonia, Cyclosporin, Tacrolimus Haematology: Haematology test, except coagulation Microbiology: Molecular test
Grey 	Sodium Fluoride Or Potassium Oxalate	2ml	Invert the tube gently 8-10 times after collection.	Chemical Pathology: Glucose, Lactate
Green 	Lithium heparin	2 ml	Invert the tube gently 8-10 times after collection.	Chemical Pathology: General chemistry Haematology: Osmotic Fragility Test
Light blue 	sodium citrate	2ml	Note: Adequate sample volume is VERY IMPORTANT. To be filled up to the indicator line. Invert the tube gently 3-4 times after collection.	Haematology: Coagulation test, Bleeding Disorder, Thrombophilia Testing,
Royal blue with red label 	Trace elements (TET) Plain	7ml	No need mixing	Trace elements or heavy metals assay in serum or urine.
Royal blue with lavender label 	Trace elements (TET) EDTA	7ml	Mix well 3 to 4 times	Trace elements or heavy metals assay in whole blood

2.5.2 Type of Container

Image	Type of container	Sample
	- Universal sterile container. Ensure the cap is tight to prevent specimen leakage - Do not add formalin for tissue culture and cytology specimens	- Chemical Pathology: Urine and other body fluid biochemistry - Medical Microbiology: Urine, body fluid and tissue culture - Haematology: Trephine biopsy - Histopathology: Small biopsy (add 10% formalin) - Cytology: FNAC specimen
	24 hr urine container	24 hr urine collection
	Stool container	- Stool C+S - Stool for rotavirus - Stool for C. diff Ag - Stool for Ova & Cyst
	PathTezt™ EasyVial™ kit	Liquid cytology preparation (LC-Prep).

Use the **appropriate containers** for different types of tests and provide an adequate sample. Specimens sent in with an incorrect container or improper/no labelling will be rejected. Refer to the Gnosis Service Guide Guideline for further details.

2.6 Labelling the Sample Container

A properly labelled sample is essential so that the test results match the patient. The key elements in labelling are:

- ❖ Patient's surname, first and middle.
- ❖ Patient's ID number.

NOTE: Both of the above patient identifiers **MUST** match the one on the requisition form.

Refer to the details below on how to label the patient's details on the sample tube or container. Failure to adhere to this will result in delayed analysis

Label the vacutainer tubes with
a) Patient's details (name & IC) can be written on the blood tubes or using a secondary label. b) If a secondary label is used, the label should cover only the primary tube label. This is important so that the sample can be visualized.

Correct way for labelling the test tubes	Incorrect way for labelling the test tubes
	

2.7 Packaging the sample

Clinical/biological samples should be placed in a sealed container or a specimen container. Refer to the relevant sections in the specific sample collection.

2.8 Test Requisition Form

Instructions For Completion of Test Requisition Form

Submission of requests for laboratory testing shall be accompanied by a GNOSIS request form. The **Request Form** must be filled in clearly (type or hand-printed).

This requisition form must contain essential information to proceed with laboratory testing. The essential elements of the requisition form are

- Patient's Full Name & second identifier (NRIC or Passport)
- Patient's age, date of birth & gender
- Date & time of specimen collection
- Diagnosis or Clinical History (Where Applicable)
- Name and signature of requesting doctor, clinic stamp and telephone number
- Special attention if required (Urgent/Phone/Fax No.)
- Nature/source of specimen
- Specimen Status (Fasting or non-fasting)
- Examination required

Mark (✓) at the appropriate box for the tests required.

Tests which are not listed in the request form should be stated under the column OTHERS.

For Histopathology, Microbiology and Virology, the type of Sample should be stated under the appropriate column.

The word "URGENT" must be written clearly or stamped preferably in red at the top on the right-hand corner of the request form.

Gnosis **Test Codes** should be written on the Request Form to indicate the tests ordered. All phoned-in verbal requests for additional test requests to be added to a written order should be followed by written confirmation as soon as possible.

If a test is ordered that can be performed by several **methodologies** and the method is not specified on the Test Request Form, the test will be performed by a method which generally has the greatest clinical utility or availability.

Urgent Requests- We will respond immediately to urgent requests during our routine hours. Urgent specimens should be packaged in our red colored marked as Urgent packaging specimen bags. It is **ESSENTIAL** to tick the urgent box on the request form and that contact details are provided for results to be telephoned, faxed or emailed when required. For urgent specimen collection, please phone our service line as stated above.

During **On-Call Hours**, our laboratory will only respond to urgent tests. An extra **RM 4.00 Surcharge** for urgent tests will be charged per case sent within On-Call Hours. If Sunday collection for non-urgent or routine tests, pre-arrangement is needed, please contact your service branch or service representative for such arrangements.

If immediate delivery of specimens to the laboratory is unavailable, please keep the specimens at a **suitable temperature**, refer to pages 30 to 33.

2.10 Add-on Test by Verbal Order

Verbal order of adding “tag-on tests” to an old specimen is **acceptable**

The ordering clinician can call the laboratory to check sample availability, suitability and place a verbal order, but must sign a supplementary Test Requisition Form and submit it to the laboratory

An **additional** or **follow-up test** can be ordered on a previously submitted specimen, provided

- there is sufficient specimen volume and
- the specimen is still usable.

written verification must be provided by filling out the Test Request Form again with an appropriate note and fax or courier to the laboratory.

2.11 Cancellation of test request

The laboratory will accept requests for **test cancellation** received before test set-up at no charge.

Cancellation requests received after test set-up cannot be honoured; the test will be performed, a report will be issued, and the client will be charged appropriately

2.12 Laboratory Rejection Criteria

The following criteria will be used to consider a sample is unacceptable and will be rejected.

- Incompletely filled or no sample identify on the Test Requisition Form
- Sample without accompanying Test Requisition Form
- Sample without any label
- Discrepancy in patient’s identity between the Test Requisition Form and sample label
- Inappropriate test sample, e.g. wrong use of container/preservative or anticoagulant
- Leaking specimen container
- Grossly haemolysed sample
- Clot found in anticoagulant tube

2.11. Turnaround time for the tests (Refer to list of tests provided by Gnosis Lab)

	Type of test	TAT (working day)
Urgent	FBC, spot/rapid test for infection (Dengue, ASOT & WWF), common biochemistry (Liver Function Tests, Renal Function Tests, Glucose), Urine FEME, etc	Same day* or 1 day * Surcharge may apply
Routine	Common test for biochemistry, hormones, serology & tumour markers; Culture, routine coagulation tests, cytology & histology, etc.	1 to 5 days
Esoteric	Special hormones/proteins & serology, molecular diagnostic, AFB culture, etc.	7 days or more

3.0 BLOOD SAMPLE COLLECTION

3.1 Wash Hands Before Venipuncture



3.2 Before sample collection,

- Correct patient identification before specimen collection is extremely important.
- Verify the identity of the patient with at least 2 identifiers (i.e., patient's name and IC/ passport number).
- Identify the patient using two different identifiers, asking open-ended questions such as, "What is your name?" and "What is your date of birth?"
- Check the requisition form for requested tests, patient information, and any special requirements and select specimen containers according to the test requests
- Verify that the patient meets preexamination requirements where relevant [e.g., fasting status, medication status (time of last dose, cessation), sample collection at predetermined time or time intervals].
- Obtain patient's consent if indicated.
- Patient comfort. Is the seating comfortable, and has the patient been seated for at least 5 minutes to avoid being rushed or confused?


3.3 Blood sample collection (Order of draw for blood specimens)

Laboratory tests are performed on anti-coagulated whole blood, plasma or serum.

The following order of draw is recommended when drawing multiple samples for laboratory testing during a single venipuncture. It is to avoid cross-contamination from tube additives.


- Blood culture tube
- Coagulation tube (e.g. blue closure)
- Serum tube with or without clot activator, with or without gel (e.g. red closure)
- Heparin tube with or without gel plasma separator (e.g. green closure)
- EDTA (e.g. lavender closure)
- Glycolytic inhibitor (e.g. grey closure)

Blood collection tubes must be drawn in a specific order to avoid cross-contamination of additives between tubes. The recommended order of draw for plastic vacutainer tubes is as below

Order of Draw				
Tube Closure Color	Collection Tube	Mix by Inverting	Min. Clot Time	
	 Blood Cultures – SPS	8 to 10 times	N/A	
	 Citrate Tube (Light Blue)	3 to 4 times	N/A	
	 Serum Separator Tubes (Gold and Tiger)	5 times	30 minutes	
	 Serum Tube (Red)	5 times (plastic) None (glass)	60 minutes	
	 Rapid Serum Tube (Orange)	5 to 6 times	5 minutes	
	 Plasma Separator Tube	8 to 10 times	N/A	
	 Heparin Tube (Green)	8 to 10 times	N/A	
	 EDTA Tube (Lavender)	8 to 10 times	N/A	
	 PPT Separator Tube (Pearl)	8 to 10 times	N/A	
	 Fluoride Tube (Gray)	8 to 10 times	N/A	

NOTE: Tubes with additives must be thoroughly mixed. Erroneous test results may be obtained when the blood is not thoroughly mixed with the additive.

3.4 Venipuncture – Blood Collection Procedure



- Carry out hand hygiene before and after each patient procedure, before putting on and after removing gloves.
- Select a suitable site for venipuncture. Avoid drawing blood below or from the infusion side to prevent dilution of the blood specimen.
- Collect the sample into appropriate tubes or containers (refer to 3.1 Type of Vacutainer Tubes)
- To avoid cross-contamination of additives between tubes, blood must be filled into the tubes in a specific order (refer table order of draw).
- Let the vacuum in the tube fill the blood up to its level. Do not press the syringe plunger as this will lead to hemolysis.
- Gently invert the tube 5-10 times
- Label the collection tubes at the bedside or drawing area. Do not pre-label the empty specimen containers before attending to the patient.
- The label should include at least 2 identifications, e.g. the patient's full name, MRN, NRIC or DOB. (Refer to labelling the sample)
- The date and time of collection must be indicated on the Test Requisition Form.
- Place specimens in the inner pocket of the specimen carrier bag and seal the zip.
- Place the Test Requisition Form in the outer pocket of the specimen carrier bag.
- Promptly send the specimens with the Test Requisition Form to the laboratory

3.5 Factors that can reliability and accuracy of the test results

Proper collection is essential to provide accurate results for patient care and management. The quality of the sample provided will determine the quality, reliability and accuracy of the test results. The table below shows common factors that can interfere with testing.

Factors	Significance and Precautions
Hemolysis	- Potassium, folate, bilirubin, AST, ALT, LDH, CK, Mg, phosphate, certain FBC parameters, and coagulation tests are markedly affected by hemolysis. - <u>To minimize hemolysis:</u> - Use a 20–22-gauge needle for routine collection. Too small a needle results in excess force, while too large a needle can cause stress on the cell walls. Avoid using narrow-gauge 'butterfly' needles where possible - Do not leave the tourniquet on for longer than three minutes. The longer the tourniquet remains on the arm, the higher the incidence of haemolysis - Warm up the puncture site. Warming increases blood flow and prevents the need to "milk" the site. - Fill tubes to the correct volume. Underfilling tubes containing anticoagulant results in a higher than recommended concentration of the additive, which promotes haemolysis. Use a smaller tube for difficult draws - Avoid transferring blood between tubes whenever possible. If you must, don't push hard on the syringe plunger, as this causes excess pressure and can also cause loss of the sample if the stopper comes off. - When using a syringe, pull the plunger gently. Pulling too quickly exerts excess pressure and will rupture the cell walls. - Place the needle correctly in the vein. If the bevel of the needle is crowded by the inner wall of the vein, this exerts force on the cells. This is typically indicated by too slow a blood flow - Avoid extreme temperatures. Never place a blood sample (blood gases, ammonia, and lactate) directly on ice, as this may cause hemolysis. - Do not shake or vigorously mix a blood specimen after collection to prevent hemolysis
Contamination	- Contamination of a blood sample may lead to an incorrect result. - Avoid taking blood from the site where an IV infusion has been set up. It can cause a dilution effect for most analytes. Depending on the type of IV infusion, it may lead to an increase in glucose, sodium, chloride, and potassium levels. - Avoid decanting blood from one sample tube to another, even if the tubes contain the same anticoagulant. - Follow the recommended 'order of draw' to avoid contamination. Example: K+EDTA contamination may lead to ❖ Falsely prolonged PT/APTT or low fibrinogen results in coagulation tests. ❖ Severely affects potassium, calcium, and ALP in chemistry tests (serum separator tubes, SST)
Venous Constriction	Vigorous constriction can severely affect calcium, lactate, electrolytes, and proteins. Avoid prolonged tourniquet application
Delay in transporting Samples (>4hrs)	- It may affect these analytes (potassium and coagulation testing), as it causes degradation of platelets, RBC, and WBC. - Suggest sending samples as soon as possible to the laboratory
Icterus	- May affect these analytes (creatinine, cholesterol, ammonia, triglycerides, D Dimer, FBC test (Haemoglobin, MCH, MCHC) and coagulation tests). - Results should be interpreted with caution

Factors	Significance and Precautions
Lipemic	May affect these analytes (sodium, ammonia, ALT, AST, salicylate, D Dimer, FBC test (Haemoglobin, MCH, MCHC) and coagulation tests). Results should be interpreted with caution.

Blood Collection or Handling Technique	Potential Error	Correct Procedure
Not allowing alcohol to air dry after cleansing the venipuncture site	- The introduction of alcohol into the specimen may cause hemolysis	• Allow alcohol to completely air dry on skin before drawing the sample.
Not following the order of draw	- Contamination from other additives could interfere with test results. - Plastic or glass serum tubes containing a clot activator may cause interference in coagulation testing.	• Always follow correct order of draw.
Improper mixing, including inadequate mixing or vigorously shaking tube after collection	- Vigorous shaking of tubes can cause hemolysis. - Inadequate mixing can cause clotting or presence of clots	Gently invert tubes the specified number of times immediately after draw: Blue top (Sodium citrate) 3 to 4 times. All other tubes (including light green/mint (PST) and lavender (EDTA) 8 to 10 times.
Under-filling or over-filling tubes	- The ratio of blood to additive is altered which can cause incorrect test results. - Examples: - Under-filling blue top sodium citrate tubes for coagulation testing can drastically alter results. - Over or under-filling blood culture bottles can result in false negative results.	Allow tube to completely fill so vacuum is exhausted. Exception is blood cultures: allow the required amount of blood to enter bottle, using guide lines marked on bottle to determine fill. For correctly filled blue top sodium citrate tubes which contain a liquid anticoagulant, the ratio of blood to anticoagulant is 9:1, which is important for accurate test results.

Blood Collection or Handling Technique	Potential Error	Correct Procedure
Combining two partially filled tubes, or filling one type of tube from another type of tube	If two different types of tube are used (e.g. lavender top into SST tube), incorrect additives can interfere with test results. If the same type of tube is used, the ratio of blood to additive is altered which can cause incorrect test results. Opening tubes can change the pH of the specimen which may affect the stability of the specimen and test result. In addition, opening tubes of blood without the use of protective equipment is a safety risk due to the possible production of aerosols or spillage.	Never combine two tubes. If blood stops flowing into the first tube before adequate volume is collected, collect a new tube. Leave tube lids on to maintain stability for some tests.
Using a partially filled tube when attempting another venipuncture.	Loss of vacuum can cause insufficient draw. Delay in mixing sample may cause clotting of specimen.	Always use a new tube when performing a second venipuncture.
Leaving tourniquet on longer than one minute	Prolonged tourniquet application may result in hemoconcentration and erroneously increased levels of protein based analytes, packed cell volume, or other cellular elements.	Do not leave tourniquet on for longer than one minute; remove as soon as possible after the blood begins to flow.
Using a winged collection device (butterfly) and not removing air in tubing when blue top sodium citrate tube for coagulation is the first tube collected	Air in the tubing will reduce the amount of blood drawn and alter the blood to anticoagulant ratio, and can cause incorrect test results.	Use a discard tube (either another blue top sodium citrate tube or a BD discard tube) to remove the air from the tubing, before collecting specimen into the blue top tube.
Delay in separation of serum or plasma due to overnight storage or delay in transit	Potentially caused of hemolysis	Arrange courier pick up as soon as possible according to test requirement.
Photolabile analytes (Specimen not protected with aluminum foil wrap/equivalent)	Low Folate, Vitamin B12, Porphyrins Neonatal Bilirubin, Vitamin A	Wrap with aluminum foil during transit and before test run.
Clots in anticoagulated blood due to difficult venipuncture or specimens not mixed well	Shortened PT Spurious results in FBC, ABG, Cyclosporin, hormones and other assays requiring whole blood specimens	Avoid prolong venipuncture period and mix specimen well.

Blood Collection or Handling Technique	Potential Error	Correct Procedure
Specimens not chilled or sent to the laboratory immediately	Spurious results in Ammonia (NH₃), Lactate, Pyruvate, ABG, Gastrin, Parathyroid Hormone (iPTH), Adrenocorticotrophic Hormone (ACTH), Renin and complement. May not identify Chlamydia, amoeba and some microorganisms because of poor viability	Keep the specimens at required temperature before picking up by lab.
Avoid using syringe to manually inject blood into vacuum tubes without taking off the needle.	Increase the risk of blood hemolysis.	Using the vacuum needles for blood withdrawal directly into vacuum tube. If using syringe, do not manual inject blood into vacuum tube.

3.6 Serum Indices – A Tool to Measure Interfering Substances in Blood Samples

Serum Indices are intended for use as part of laboratory practice to monitor the instrument response to detect hemolyzed, icteric, or lipemic samples. Hemolysis, icterus, and lipemia (HIL) are the most commonly tested interferences that may affect the integrity of patient samples.

The flags indicated in report characterize the kind of chromatic substance (LIP: Lipaema/turbidity, ICT: Bilirubin and HEM: Haemoglobin) and approximate concentration of the interferent as in the following table:

Flag	LIP (mg/dL Intralipid)	ICT (mg/dL Bilirubin)	HEM (mg/dL Hemoglobin)
N	< 40	< 2.5	< 50
+	40 – 99	2.5 – 4.9	50 – 99
++	100 – 199	5.0 – 9.9	100 – 199
+++	200 – 299	10 – 19.9	200 – 299
++++	300 – 500	20 – 40	300 – 500
+++++	> 500	>40	>500

Kindly refer to the table below for Hemolysis, icterus, and lipemia (HIL) toleration level for each test.

Immunoassay

Assay	Lipid interference		Icterus interference		Hemolysis interference		Remark
	mg/dL	Flag	mg/dL	Flag	mg/dL	Flag	
Cortisol	1800	+++++	10	+++	500	++++	
Ferritin	900	+++++	5	++	300	++++	
Folate	1800	+++++	10	+++	Avoid	Not Applicable	Do not use hemolyzed samples. The folate level in red cells is much greater than that of the serum or plasma (heparin), leading to spuriously high results
Vitamin B12	1800	+++++	10	+++	Avoid	Not Applicable	
iPTH	3000	+++++	20	++++	500	++++	
Vitamin D	3280	+++++	40	++++	50	++	Avoid hemolysed samples
hs-Troponin I	3000	+++++	40	++++	400	++++	
Insulin	1800	+++++	10	+++	Avoid	Not Applicable	Hemolysis releases enzymes which degrade insulin
AMH	666	+++++	43	+++++	300	++++	
DHEAS	1750	+++++	30	++++	1000	+++++	
FSH	1800	+++++	10	+++	1000	+++++	
LH	1800	+++++	10	+++	300	++++	
PAPP-A	3000	+++++	40	++++	500	++++	
Progesterone	450	++++	5	++	500	++++	
Prolactin	1800	+++++	10	+++	500	++++	
SNSE2	666	+++++	40	++++	300	++++	
SHBG	5000	+++++	30	++++	400	++++	
β-HCG	3000	+++++	40	++++	500	++++	

Assay	Lipid interference		Icterus interference		Hemolysis interference		Remark
	mg/dL	Flag	mg/dL	Flag	mg/dL	Flag	
Testosterone	1800	+++++	10	+++	1000	+++++	
Estradiol	1800	+++++	20	++++	500	++++	
AFP	520	+++++	25	++++	1200	+++++	
CA153	3000	+++++	40	++++	500	++++	
CEA	1800	+++++	30	++++	500	++++	
Free PSA	1500	+++++	20	++++	500	++++	
CA199	1000	+++++	60	+++++	50	++	
CA125	1800	+++++	20	++++	1000	+++++	
PSA	1500	+++++	20	++++	500	++++	

Chemistry

Assay	Lipaemic interference		Icterus interference		Hemolysis interference		Remark
	mg/dL	Flag	mg/dL	Flag	mg/dL	Flag	
Albumin BCG	800	+++++	40	+++++	450	+++++	
ALP	100	+++++	28	++++	450	+++++	
ALT	300	+++++	40	+++++	500	+++++	
Amylase	1000	+++++	40	+++++	500	+++++	
AST	300	+++++	40	+++++		+	
Calcium Arsenazo	1000	+++++	40	+++++	500	+++++	
Creatinine Enzymatic	600	+++++	40	+++++	500	+++++	
Cholesterol	1000	+++++	8	++	500	++++	
Creatinine	600	+++++	40	+++++	500	+++++	
DDimer	700	+++++	40	+++++	500	+++++	
Direct Bilirubin	300	+++++		+++++		+	
GGT	1000	+++++	40	+++++	250	+++++	
Glucose	700	++++	40	++++	500	+++++	
HBA1C (B00389)	500	+++++	30	+++++		+++++	
HDL-C	900	+++++	40	+++++	500	+++++	
Iron	100	+	40	+++++	100	+	
LDL-R	1000	++++	40	+++++	500	+++++	
Magnesium	200	++	28	++++	150	++	
Phosphorus	800	+++++	40	+++++	Avoid	+	Hemolysis must be avoided as Phosphate may be split off from labile esters in the erythrocytes.
Total Bilirubin	1000	+++++		+++++	45	+	
Total Protein	1000	+++++	24	+++	300	+++	
Transferrin	1000	+++++	40	+++++	500	+++++	
Urea	500	+++++	20	+++	250	+++++	
Uric Acid	1000	+++++	40	+++++	500	+++++	

Assay	Lipaemic interference		Icterus interference		Hemolysis interference		Remark
	mg/dL	Flag	mg/dL	Flag	mg/dL	Flag	
Triglyceride	1000	+++++	40	+++++	500	+++++	Grossly lipemic samples under rare circumstances may evade the Data Check Parameters (Flag: F, Z, @, &) and should routinely be diluted 1 part sample to 4 parts salines prior to analysis, and the results multiplied by 5.
HsCRP	1000	+++++	40	+++++	500	+++++	
*Apo A1	900	+++++	40	+++++	500	+++++	
Apo B	200	+++	40	+++++	500	+++++	
RF	750	+++++	40	+++++	500	+++++	
CHE	1000	+++++	40	+++++	500	+++++	
CK	1000	+++++	40	+++++	500	+++++	
LDH	1000	+++++	40	+++++		+	
Na	500	+++++	40	+++++	500	+++++	
K	500	+++++	40	+++++	50	+	
CL	500	+++++	40	+++++	500	+++++	

Adopted from respective reagent insert.

Flag	Lipaemia (LIP)			Icterus (ICT)			Haemolysis (HEM)		
	Analyte	Significance Level Used*	Effect	Analyte	Significance Level Used*	Effect	Analyte	Significance Level Used*	Effect
+	Iron OSR6x86	6%	↑				AST OSR6x09	11%	↑
	Prealbumin OSR6x75	10%	↓				Bilirubin-D OSR6x11	12%	↓
							Bilirubin-T OSR6x12 (normal setting)	12%	↓
							CK-MB OSR6x155	10% or 5 U/L	↑
							HBDH OSR6x29	8%	↑
							Iron OSR6x86	6%	↑↓
							LDH OSR 6x26	8%	↑
							Potassium	4%	↑
							Haptoglobin OSR6x65	10%	↓
							Inorg. Phosphorus OSR6x22	8%	↑
++	Ceruloplasmin OSR6x64	10%	↑	Cholesterol OSR6x16	6%	↓	Magnesium OSR6x89	6%	↑
	Magnesium OSR6x89	16%	↑						
+++	Apo B OSR6x43	10%	↓	Lactate OSR6x93	9%	↓	Amylase OSR6x06	10%	↓
	IgM OSR6x173 (AU5800 only)	12%	↑↓	Lipase OSR6x30	10%	↓	Total Protein OSR6x32	5%	↑
				Total Protein OSR6x32	5%	↓			
				Urea OSR6x34	8%	↓			
++++	Ferritin OSR6x203	10%	↓	ALP OSR6x04	11%	↑	Cholesterol OSR6x16	6%	↑
	Glucose OSR6x21	6%	↓	Amylase OSR6x06	10%	↑			
	LDL Cholesterol OSR6x83	6%	↑	Glucose OSR6x21	6%	↑			
				Magnesium OSR6x89	6%	↑			
++++ +	All remaining reagents			All remaining reagents			Bilirubin-T OSR6x12 (small volume setting)		
							All remaining reagents		

* Significance level is the level above which interreference is deemed significant for the particular reagent, % is adapted from RILIBAK edition 2003

↑ Positive Interference

↓ Negative Interference

↑↓ Depending on the analyte concentration of the sample you may observe positive or negative interference

Note: The effect of the interference can depend on the concentration of analyte in the sample and sample matrix

4.0 SPECIAL SPECIMEN COLLECTION PROCEDURES FOR BIOCHEMISTRY TESTS

4.1 24-HOUR URINE COLLECTION

Most quantitative assays are performed on a urine specimen collected over 24 hours. The 24-hour Timing allows for circadian rhythmic changes in excretion at certain times of day.

Procedure of collection:

- a) The 24-hour urine bottle, which contains a preservative for the required test, is available at The Genosis Lab/branches and provided on request, with the accompanying request form or note.
- b) On the day of collection, the first urine voided must be thrown away. Time of first urine voided is the start of the timing for the 24-hour collection.
- c) Collect the second and subsequent voided urine for 24 hours from the timed start into the 24-hour urine bottle.
- d) For a male patient, it is advisable NOT to void the urine directly into the 24-hour urine bottle. This is to avoid possible chemical burns.
- e) At the end of 24 hours, the last urine voided is collected. For the best result, refrigerate the sample.
- f) Label the bottle as directed and send immediately to the laboratory.

Examples of the tests: 24-hours urine cortisol and 24-hours urine catecholamine

4.2 24-HOUR URINE COLLECTION for CATECHOLAMINES

- a) Please refer to the procedure for 24-hour urine collection to collect urine for 24-hour urine catecholamines.
- b) Please note that 10 ml of 25% HCl is added to the bottle to preserve the analytes. It is
- c) important for the requesting physician to advise the patient NOT to discard the
- d) preservative.
- e) Instructions on patient preparation and specimen collection:
 - Abstain from bananas, coffee, pineapple and walnuts one day before and during the 24-hour urine collection.
 - Certain drugs alter the metabolism of catecholamines. It is advisable to stop such medications at least one day before urine sampling. The medications include: Alpha2 agonists, Calcium channel blockers, ACE inhibitors, Bromocriptine, Methyldopa, Monoamine oxidase inhibitors, Alpha blockers and Beta blockers, Phenothiazines and Tricyclic antidepressants.
- f) Please advise the patient to avoid stress, exercise, and smoking before and during urine collection

Patient Information Sheet

24-hour urine collection

Please read and follow these instructions carefully.

- You must use the collection bottle provided by Gnosis Laboratories
- **Do not** discard or touch any of the preservatives in the bottle.
- Keep the lid on tight



Collecting the specimen

Drink your normal amount of fluids during the 24 hours

Day 1

- When you get up (e.g. 7:30 am) pass urine into the toilet.
- Do **not** collect the first urine
- Please collect the subsequent urine you void throughout the day and night.
- In the collection bottle
- Write the **date, time, your name and IC No.** on the collection bottle label.

Collect ALL urine for 24 hours

- Use a clean plastic container
- Pour the urine into the collection bottle
- Store the specimen in a cool place

Rinse the plastic container after each use.



Day 2

- Collect only the first morning sample of urine when you get up (e.g. 7:30am).
- Add it to the collection bottle
- This is the end of the 24-hour collection. Write the **date and time** on the label.

Delivering the specimen

Deliver the specimen promptly to your Gnosis Laboratory (HQ) or nearest Gnosis branch



Your results

Your doctor will advise you when the results are available

5.0 SPECIMEN COLLECTION FOR MICROBIOLOGY TEST

5.1 General Guidelines for Proper Specimen Collection and Transport

- a) Specimens shall be collected before administering antimicrobial agents, where possible.
- b) Use sterile containers and aseptic technique to collect specimens.
- c) Collect an adequate amount of specimens. Inadequate amounts of specimens may affect the accuracy of test results.
- d) Swabs shall be transported in suitable media.
- e) Specimens collected by using needle aspiration should be transferred to a sterile container and transported to the laboratory as soon as possible. If there is only a small volume of
Add sterile saline to the material in the syringe, mix well, and then transfer it to a sterile container.
- f) All specimens from high-risk patients (HIV, Hep B, TB, and others) must be marked as high risk.
- g) The specimen container must be properly labelled, placed in a biohazard plastic bag and accompanied by a completed laboratory Test Requisition Form.
- h) Specimens should be transported to the laboratory soonest possible and preferably within the same day.

Special Instructions

5.2 Urine Culture

a) Sterile container

A clean mid-stream Urine for culture should be collected in a sterile 90mL urine container and refrigerated while waiting for specimen pick up from the laboratory.

b) Labelling Requirement on the Specimen container

Provide information as required in the label of the urine container, such as full name, IC Number, source of specimen and date and time of collection.

c) Request form

- The patient's full name, I.C. Number, source of specimen and date and time of collection should be specified on the Test Requisition Form and the urine container.
- Relevant information, such as pregnancy, antibiotic medication, drug allergies, etc., shall be indicated in the requisition form.

d) Collection of a Mid-stream Urine Sample

- Urine collected at any time of the day is acceptable, preferably an early morning urine specimen.
- Provide the following instructions to the patient:
 - Wash and dry your hands thoroughly.
 - Remove the container lid. Do not touch the inner surfaces of the container.
 - Wash your urogenital area ("lower parts") with the towelette
 - For women, wipe from front to back between the folds of skin
 - For men, retract the foreskin (if uncircumcised), and clean the glans (head of the penis)
 - Pass a small amount of urine into the toilet (a woman needs to hold the skin folds apart) and then, midway through urination, urinate into the container.
 - The container should only be 1/2 to 2/3 full.
 - A specimen that contains stool, vaginal discharge, or menstrual blood cannot be used.
 - Replace the lid and tighten firmly.
 - Wash and dry your hands thoroughly.
 - Immediately refrigerate the specimen and send it to the laboratory within 24 hours. Urine specimens shall be maintained at 2- 8 °C during transportation. Call the laboratory for further advice if the specimen is expected to be collected more than 24 hours.

Patient Information Sheet

Mid-stream urine collection

Introduction

The purpose of this leaflet is to explain how adults should collect a midstream urine (MSU) sample (specimen).

What is a midstream urine sample?

- Urine is normally sterile, so if bacteria is present, it means that there is an infection.
- A midstream urine (MSU) sample is used to confirm a diagnosis of a urine infection, and the best antibiotics to prescribe to treat the infection.
- An MSU sample describes the middle part of your urine flow; you do not collect the first or last part of urine flow. By collecting the middle part of the flow of urine, the risk of the sample being contaminated with bacteria from your hands or skin around the urethra (the tube that carries urine out of the body) is reduced.

How to collect a Mid-stream urine sample

Wash hands with soap and water, rinse and dry hands	
Remove the lid from the collection container and set it aside. Avoid touching the inside of the collection container and lid.	
Void (pee) a small portion of urine into the toilet. Momentarily stop the urine flow, then resume the flow and collect a portion of the urine into the container Instructions for women: It is advised to hold open the labia (entrance to the vagina) and pass some urine into the toilet (about 15 to 30 ml). Then, without stopping the flow of urine, pass urine into the sterile urine container Instructions for men: - Retract the foreskin. - Pass the first part of the stream of urine (about 15 to 30 ml) into a urinal, toilet or bedpan/bottle. - Place the sterile urine container (into the urine stream without interrupting the flow. Collect the mid-stream part of the urine. Continue the remaining part of the urine stream into the toilet	 
Tightly secure the lid	
Wash hands thoroughly	
Write the date and time of collection on the urine container(s) label and on the laboratory request form.	
If collecting at home and delay is unavoidable, keep the specimen in the refrigerator and bring it to the laboratory as soon as possible.	

5.3 Blood Culture

Aseptic technique shall be in practice, which is critical for proper blood culture collection. Source of blood collection: Venous blood

Acute Sepsis: Collect **two or three** sets of culture from **separately prepared sites** before initiating antimicrobial therapy. Each set consists of two bottles, one aerobic and one anaerobic or two aerobic.

Acute Endocarditis:

Obtain **three** blood cultures from **separate venipuncture sites** over 1 – 2 hours, before initiating therapy. These cultures are often obtained **30 minutes apart** to document persistent bacteremia.


Subacute Endocarditis:

Obtain **three** blood cultures on **day 1** (15 minutes or more apart). If cultures are negative after 24 hours, obtain 3 more.

Adults: 10 ml of blood per culture bottle. In the event that **less** than 10 ml of blood is obtained from an adult, put it all into **one aerobic** blood culture bottle.

Children and infants: 1 – 3 ml of blood per culture bottle. The minimum volume is dependent upon the weight of the child/infant, Please contact the microbiology department before obtaining the blood if assistance is needed in determining the correct amount of blood needed for the child/infant.

5.4 Nasal Swab



Nasopharyngeal Swab Procedure

- Wear a surgical mask and disposable gloves.
- Wash hands thoroughly with soap and water or alcohol-based hand gel (before and after the procedure)
- Remove the patient's surgical mask to perform the procedure and replace it with a new one when done.
- Use a flexible, fine-shafted aluminum swab with a polyester tip.
- The distance from the patient's nose to the ear gives an estimate of the distance the swab should be inserted.
- Insert the swab into one nostril down and backwards into the nasopharynx and leave in place for a few seconds.
- Slowly withdraw the swab with a rotating motion.
- Place the tip of the swab into a vial containing 2–3 ml of Viral Transport Medium and cut the shaft.
- Dispose of all PPE and other contaminated materials in the trash.
- Storage Condition
- Specimens can be kept refrigerated at **4°C for up to 72 hours**
- Specimens that cannot be processed within 48-72 hours should be kept in the refrigerator at **4°C**.

5.5 Genital Tract Swabs

Clinical indication

Genital Infections, Sexually Transmitted Diseases,

Specimen Required

Female: Cervical or High vaginal swabs, Urethral swabs

Male: Urethral swab, penile swab

Method for collection

Cervical or High vaginal swabs

Use a speculum to take Cervical and high vaginal swabs.

Avoid vulvar contamination of the swab.

High Vaginal Swabs


Roll firmly the swab over the surface of the vaginal vault. Then place the swab in the transport medium.

Cervical Swabs

Rotate the swab inside the endocervix. The swab should then be placed in the transport medium.

Urethral Swabs

- Practice aseptic technique to avoid contamination with microorganisms from the vulva or the foreskin. Thin swabs are available for the collection of specimens.
- The patient should not have passed urine for at least 1 hour.
- The swab is gently passed through the urethral meatus and rotated. Place the swab in the transport medium.




Intrauterine Contraceptive Devices (IUCDs)

The entire device should be sent in a sterile universal container.

5.6 Rectal Swabs

- Rectal swabs should be taken via a proctoscope.
- Advantages of rectal swabs:
 - Convenient
 - Adapted to small children, debilitated patients and other situations where a voided stool sample is not feasible
- Drawbacks of rectal swabs:
 - No macroscopic assessment possible
 - Less material available
 - Not recommended for viruses



5.7 Pus Samples/ Wound Swabs

- Wound swabs should only be taken when signs of clinical infection are relevant.
- Wound or Pus samples are screened for all likely bacterial pathogens, and if present, these organisms and their antibiotic sensitivity results will be reported. The inclusion of relevant clinical information on the Test Requisition Form will assist in determining the bacterial isolates.
- Please indicate clearly on the requisition form and the swab site of the wound to facilitate interpretation of culture results.
- Specimens Required

Pus sample (preferably to a wound or pus swab) in a sterile container.


Wound swab in transport medium.

5.8 Abscess

- Decontaminate the surface with 70-95% alcohol and 1-2% tincture of iodine.
- Collect the purulent material aseptically from an undrained abscess, using a **sterile needle and syringe**.
- Open abscesses with a sterile scalpel and collect the expressed material with a sterile needle and syringe.
- Transfer 5-10 ml of the aspirated material to an **anaerobic** transport vial. Transport immediately. *Anaerobic transport media is **not recommended** for AFB culture. If requesting AFB culture, transfer at least 1 ml of the aspirated material into a sterile container.*
- Swabs are not recommended** because
 - They dry easily because of the limited amount of material obtained.
 - Swabs are not optimal for fungal, anaerobic cultures, or decubitus ulcers.
 - Swabs are **not** accepted for mycobacterial cultures, perirectal abscesses, or oral abscesses.
 - Gram stains cannot be provided from a single swab. If a Gram stain is needed, collect two swabs.


5.9 Eye Swab

- Explain the procedure and the purpose of the investigation to the patient to obtain informed consent, gain cooperation, and allay any fears and anxieties.
- Sit or lie the patient with head well-supported and with the chair at an appropriate height to ensure safety for the patient and the nurse.
- Perform hand washing to reduce the risk of cross-infection
- Ask the patient to look up and gently pull down the lower lid, exposing the conjunctiva.
- Gently sweep the swab stick along the lower fornix, from inner to outer canthus. Do not touch the eyelids.
- Swab I s p l a c e d immediately into the bacterial medium container.
- Ask the patient to close the eye for a few seconds. This will ensure a safe technique of swab taking and avoid damage to the cornea.
- Repeat the procedure on the other eye with a separate swab, if needed.
- Wash hands in between to minimize the risk of contamination of the other eye.



5.10 Throat Swab

- a) Hold the tongue away with a tongue depressor.
- b) Locate areas of inflammation and exudate in the posterior pharynx, tonsillar region of the throat behind the Uvula.
- c) Avoid swabbing the soft palate.
- d) Do not touch the tongue.
- e) Rub the affected area back and forth with a swab



5.11 Sputum Collection

Instructions to the patient:

- a) Gargle or rinse mouth with water.
- b) Instruct the patient to cough deeply to produce a specimen from the lower respiratory tract and not saliva.
- c) Collect in a plain sterile container, with a sufficient amount depending on the number of tests requested if > 24 hours, refrigerate at 4 to 8°C

6.0 SPECIAL PROCEDURES FOR HISTOPATHOLOGY AND CYTOLOGY TEST

6.1 Histopathology

Use separate Histopathology and Cytology request forms for the same patient.

Specimen Container Guidelines

- a) Use preferably transparent containers so that laboratory and other staff can see and verify the specimen without having to open the cap.
- b) Size is adequate so that it has enough capacity to hold the specimen, with at least three times its volume of fixative.
- c) Containers should be appropriately labelled and tally with the Test Requisition Form.

Fixative

- a) **10% buffered neutral formalin** solution is recommended for routine fixation. For large specimens, please cut open the tissue to facilitate penetration of the fixative. Formalin usually does not penetrate tissues for more than a depth of about 1.0cm.
- b) Tissues not placed in fixatives will undergo **autolysis**. Lysed blood could be seen in the solution. The tissue will not change dull chocolate brown. Please transfer the specimen to formalin fixative if this is occurring.

Small Biopsies

- a) Punch biopsies (endoscopic, bronchoscopy and trucut biopsies, aspiration biopsies, etc) are preferably mounted on pieces of paper before placing them in the fixative. This helps to reduce tissue loss and damage.
- b) If incisional biopsies are done, try to obtain wedges of tissue instead of irregular fragments. Irregular fragments are difficult to orient and interpret. In general, the larger the lesion, the bigger the incisional biopsy specimen.
- c) Biopsies from multiple sites should be placed in different containers.

6.2 Gynaecological Pap Smears (Pap Test)

Indication


- a) The Pap smear is primarily for the detection of cervical premalignant and malignant changes and should not be relied upon to detect endometrial malignancy.
- b) Patient Preparation:
 - Do not use a vaginal douche or topical vaginal medications for 48 hours before examination.
 - Do not have sexual intercourse for 24 hours before examination.
 - Schedule examination 14 days after the onset of the last menstrual period.
- c) Include the clinical information in request form, as it helps in the interpretation of the specimen.

6.2.1 Conventional Pap Smear Preparation

- a) Label the slide with at least 2 identifiers (e.g. patient's name, IC, passport number or MRN).
- b) Collect a sample with a spatula, followed by the cytobrush.
- c) Use the spatula for scraping the ectocervix. The brush specimen should be in addition to, never instead of, the ectocervical scraping.
- d) Smears should be made with **one or two swipes** of the spatula on the slide, not with a mixing motion. The cytobrush should be **rolled** on the slide.
- e) The smears should be fixed immediately with 95% ethyl alcohol for 15 – 30 minutes to avoid air-drying. If an aerosol spray is used, fix the smear for 10 minutes. The spray nozzle should be about **twelve inches (30 cm)** from the slide. If held too close, the spray “freezes” the cells and also lifts them from the slide, causing them to clump.
- f) Fixed smears should be allowed to dry for 10 minutes before placing them into the slide carrier for dispatch to the laboratory.
- g) Submit to the laboratory using one test requisition form.

6.2.2 Liquid-Based Cytology (LBC) Preparation using PathTezt /EasyVial

- a) Step 1: Label the LBC vial with at least 2 identifiers (e.g. patient's name, IC, passport number or MRN).
- b) Step 2:



Remove the Disposable Cell Sampling Device (PathTezt® Cyto-brush, Nylon Swab) from its packaging.

- c) Step 3:




Insert the Disposable Cell Sampling Device (PathTezt® Cyto-brush, Nylon Swab) in the endocervical canal.

- d) Step 4:



Rotate the Disposable Cell Sampling Device (PathTezt® Cyto-brush, Nylon Swab) one time.

- e) Step 5:



A. Liquid-Based Pap Preparation

1. Insert the Disposable Cell Sampling Device (PathTest® Cyto-brush, Nylon Swab) into the vial with preservative fluid and follow the instruction given by the manufacturer of the Pap Preparation method.
2. Reseal the vial.

Adequacy of Smears

Smears may be unsatisfactory for reporting due to the following:

- a) The presence of an endocervical component (endocervical or metaplastic cells) is generally considered necessary to classify a smear as a satisfactory specimen.
- b) However, we have found positive smears even in the absence of an endocervical component and the data available is not conclusive as to whether the absence of an endocervical component will increase the risk of a false negative smear.
- c) In addition, some smears are also taken without sampling of the endocervical canal and are not expected to contain an endocervical component. Hence, we may report PAP smears without an endocervical component as satisfactory, but the absence of this component will be recorded in the report.
- d) Unsatisfactory smear criteria
 - Inadequate cells in the smear
 - **Too thick a smear**
 - Too much blood, secretions or contaminating lubricants in the smear
 - Too many inflammatory cells
 - Too many crushed artefacts
 - Poorly fixed smears or severe air drying artefacts

6.3 Non-Gynaecological Cytology

For Urine, body cavity fluids, cerebrospinal fluids and secretions,

- a) if delivery to the laboratory is not immediate, the specimen should be refrigerated or transported in a cold chain.
- b) Smears from FNAC procedures should be **fixed immediately**.
- c) Please provide at least two air-dried and alcohol-fixed smears.

7.0 SEMEN COLLECTION

To obtain an optimal sperm count, a period of abstinence from sexual activity is required for a minimum of 2 days and a maximum of 7 days before collection of the specimen. 3-5 days of abstinence is recommended. The best results are obtained when the specimen is collected by masturbation and ejaculated into a wide-mouth sterile plastic container provided

Please ensure your full name, date of birth, date and time of collection are recorded on the container.

NOTE:

Other methods of collection, for example, Coitus interruptus or withdrawal just before ejaculation, are subject to errors. Regular condoms, sheaths and lubricants all interfere with the results of seminal assays and should not be used

The specimen should be kept at room temperature (NOT REFRIGERATED) and must be delivered to Gnosis Laboratory within one hour after collection, between Monday to Friday 8.30am – 5.00pm or Saturdays between 8.30am and 1.00pm.

Transportation:

The sample should be protected from extremes of temperatures (less than 20 degree Celsius and more than 35 degrees Celsius).

Place the specimen in a specimen bag and carry on the inside of a pocket or a handbag.

The specimen must be submitted with a signed request form (given by the referring doctor).

NOTE: If a second specimen is required for testing, it must be submitted with a separate request form signed by the referring doctor. The interval between the two collections should not be before seven days and not later than three weeks.

COLLECTION AND SAMPLE INFORMATION (Please complete details in the section below)

Time of Ejaculation: _____ am/pm

Number of days of abstinence: _____

Please indicate if this collection is complete (circle one only) Full / Partial Ejaculate

Patient Information Sheet : Semen Collection

Your sample is examined for the number of sperm present (a sperm count), the ability of the sperm to move (motility), the shape and appearance of the sperm (morphology), the total volume of the ejaculate, clumping and the vitality of the sperm

Follow these instructions carefully to ensure your test results are accurate and reliable

Sample Collection:

- In order to obtain an optimal sperm count, a period of abstinence from sexual activity is required for a minimum of 2 days and a maximum of 7 days before collection of the specimen. 3-5 days abstinence is recommended.
- The best results are obtained when the specimen is collected by masturbation and ejaculated into a wide mouth sterile plastic container provided
- Please ensure your full name, date of birth, date and time of collection are recorded on the container.

NOTE:

Other methods of collection for example – Coitus interruptus or withdrawal just prior to ejaculation, is subject to errors. Regular condoms, sheaths and lubricants all interfere with the results of seminal assays and should not be used

The specimen should be kept at room temperature (NOT REFRIGERATED) and must be delivered to Gnosis Laboratory within one hour after collection between Monday to Friday 8.30am – 5.00pm or Saturdays between 8.30am and 1.00pm.

Transportation:

- The sample should be protected from extremes of temperatures (less than 20 degree Celsius and more than 37 degree Celsius).
 - Place the specimen in a specimen bag and carry on the inside of a pocket or a handbag.
 - The specimen must be submitted with a signed request form (given by the referring doctor).
- NOTE: If a second specimen is required for testing, it must be submitted with a separate request form signed by the referring doctor. The interval between the two collections should not be before seven days and not later than three weeks.

COLLECTION AND SAMPLE INFORMATION (Please complete details in the section below)

1. Time of Ejaculation: _____ am/pm
2. Number of days of abstinence: _____
3. Please indicate if this collection is complete (circle one only) Full / Partial Ejaculate

8.0 CRITICAL LABORATORY VALUES

Critical laboratory result is test result or value that falls into critical limits or the presence of any unexpected abnormal findings, cells or organisms which may cause imminent danger to the patient, and/or require immediate medical attention.

Notification shall be given to the clinician who had ordered the test or to the authorised personnel if the responsible clinician is not around.

Critical Limit For Haematology					
Values for Adults			Values for Paediatric		
Lower Critical Limit	Analytes	Upper Critical Limits	Lower Critical Limit	Analytes	Upper Critical Limits
6.0 g/dL	Haemoglobin	19.0 g/dL	7.0 g/dL	Haemoglobin (Peads)	20.0 g/dL
			8.0 g/dL	Haemoglobin (Neonate)	22.0 g/dL
20%	Hematocrit	60%	20%	Hematocrit (Peads)	40%
			25%	Hematocrit (Neonate)	70%
20 thou/cumm	Platelet	1000 thou/cumm	50 thou/cumm	Platelet	1000 thou/cumm
-	-	-	2.0 thou/cumm	WBC, Total	50.0 thou/cumm
-	INR (Ratio)	>5	-	INR (Ratio)	>5
-	PT	> 2.5X upper reference limit	-	-	-
-	APTT	> 80 Seconds or 2X upper reference limit	-	-	-
1.0 g/L	Fibrinogen	-	0.7 g/L	Fibrinogen	-

Adopted from Quick Guide for Improving Notification of Critical Laboratory Results in MOH Hospitals 2020

Critical Limit For Chemical Pathology					
Values for Adults			Values for Paediatric		
Lower Critical Limit	Analytes	Upper Critical Limits	Lower Critical Limit	Analytes	Upper Critical Limits
2.8 mmol/L	Potassium	6.0 mmol/L*	2.8 mmol/L	Potassium	6.0 mmol/L
125 mmol/L	Sodium	155 mmol/L	125 mmol/L	Sodium	155 mmol/L
2.8 mmol/L	Glucose	20 mmol/L	1.6 mmol/L	CSF-Glucose	-
1.5 mmol/L	Calcium	3.0 mmol/L	1.7 mmol/L	Calcium	3.1 mmol/L
0.41 mmol/L	Magnesium	2.0 mmol/L	0.5 mmol/L	Magnesium	1.8 mmol/L
0.32 mmol/L	Phosphate	2.87 mmol/L*	0.4 mmol/L	Phosphate	2.8 mmol/L
-	Troponin I (CLIA)	11.6 pg/mL (F) 19.8 pg/mL (M)	-	Troponin I (CLIA)	11.6 pg/mL (F) 19.8 pg/mL (M)
-	Troponin I (FIA)	0.04 ng/mL	-	Troponin I (FIA)	0.04 ng/mL
-	Troponin I (Qualitative)	Positive	-	Troponin I (Qualitative)	Positive
-	D-dimer	0.50 mg/L	-	D-dimer	0.50 mg/L
-	-	-	-	Urea	19.0 mmol/L
-	-	-	-	Creatinine	330 umol/L
-	-	-	-	Ammonia	100 umol/L
-	-	-	-	Bilirubin (Neonate)	513 umol/L
-	-	-	-	Bilirubin (Peads)	428 umol/L
-	Creatinine kinase	5,000 U/L	-	-	-
-	-	-	-	Uric Acid	500 umol/L
-	-	-	-	CSF-Protein	1.87 g/L
250 mmol/kg	Serum Osmolality	350 mmol/kg	250 mmol/kg	Serum Osmolality	310 mmol/kg
-	Lithium	1.5 mmol/L	-	-	-
-	-	-	-	TSH (Neonate)	20 mIU/L
-	Free T4	>64.35 pmol/L	-	-	-

Adopted from Quick Guide for Improving Notification of Critical Laboratory Results in MOH Hospitals 2020

Critical Findings for Microbiology

Test	Results
Cerebrospinal fluid C&S	Microscopic result (N or abN)
Cerebrospinal fluid Ag	Positive rapid Antigen detection
Blood Culture	Positive result Gram stain/culture
Sterile body fluids	Positive result, gram stain/culture
Acid Fast Bacilli	Positive smear result /culture
Malaria Parasite	Presence of a parasite on the blood film
Stool Culture	Salmonella typhi, Vibrio cholerae, Shigella, E. coli O157
Any Type Culture	ESBLs, MRSA, MRO, VRE, VRSA.
Antigen detection	Legionella sp
Prenasal swab	Bordetella Pertussis, Corynebacterium diptheria

9.0 List of tests provided by Gnosis Laboratories

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
17A0	17-Hydroxyprogesterone (17-OHP)	M : 0.55-1.99 ng/mL F: Follicular phase : 0.21-1.45 ng/mL Corpus luteum : 0.61-2.88 ng/mL Post Men: 0.16-0.79 ng/mL	RIA	5 ml Plain, <i>Separate serum & freeze. Specify the age, sex, and phase of the cycle. For women, the sample must be taken at the start of the follicular phase.</i>	10
17KS	17-Ketosteroids (17-KS)	M:10.00-25.00 mg/day F:6.00-14.00 mg/day	Column and Colorimetric	24-hour urine collection <i>In an acid preservative or Refrigeration</i>	10
5HI	5-Hydroxyindoleacetic Acid (5-HIAA), Carcinoid Syndrome	2.00-8.00 mg/day	HPLC	24-hour Urine, <i>In acid preservative or Refrigeration</i>	10
ACH	Acetylcholine Receptor Ab (AchR Ab)	<0.50 nmol/L	RIA	5 ml Plain, <i>Separate the serum and freeze</i>	7 -14
AFBC	Acid Fast Bacilli (AFB) Concentrated (Membrane-based Smear)	Not seen	concentrated sandwich smear	Sputum/Pleural Fluid/ FMU/ CSF/ Swab <i>Significantly higher sensitivity than direct smear.</i>	2
AFBS	Acid Fast Bacilli (AFB) ZN Stain (Direct Smear)	Not seen	bacteriological staining method	Sputum/Pleural Fluid/ FMU/ CSF/ Swab <i>Collect fresh sputum recommended on three consecutive days or early morning urine or pleural fluid, CSF, or swab.</i>	2
ACPP	Acid Phosphatase, Prostatic	<3.5 ng/mL	CLIA	5 ml Plain	7
APTT	Activated Partial Thrombin Time (APTT)	-	Stago coagulation system	2 ml Citrate <i>If possible, please specify if the patient is on an anticoagulation treatment as well as the clinical context.</i>	2
ADA	Adenosine Deaminase (ADA), pleural fluid	<40 U/L	Enzymatic	Pleural Fluid	10-14
ADENO	Adenovirus DNA (by PCR)	Not Detected	PCR	Discharge/ Aspirate/ Swab	7
ACTH	Adrenocorticotrophic Hormone (ACTH)	7.2 – 63.3pg/ml	CLIA	3 ml EDTA (Plasma)	7

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
				<i>Not to be performed on a haemolysed sample. Sample on a cooled tube at 4°C, centrifuge a.s.a.p and freeze the plasma.</i>	
ALT	Alanine Aminotransferase (ALT/SGPT)	M: <50 U/L F: <35 U/L	UV/NADH	5 ml Plain	1
ALB	Albumin	32 – 52 g/l	BCG method	5 ml Plain	1
FALD	Aldosterone, Urine	2.84-33.99 µg/day;	RIA	24hr Urine, <i>In acid preservative or Refrigeration</i>	7
ALD	Aldosterone, Serum	Vertical: 48.30-270.00 pg/ml; Recumbent: 68.00-173.00pg/ml	CLIA	5 ml Plain <i>Do not refer to haemolysed or lipaemic samples. Specify upright or reclined (Sampling in upright position after 1 hr walking; sampling in reclined position after 1 hr in supine position).</i>	7
ALKP	Alkaline Phosphatase (ALP)	Male 0 to < 15 days : 76-233 U/L 15 days to < 1 year : 76 - 443 U/L 1 to 9 years : 132 - 315 U/L 10 to 12 years : 119 - 393 U/L 13 to 14 years : 52 - 239 U/L 15 to 16 years : 45 - 108 U/L 17 to 18 years : 40 - 80 U/L ≥19 years : 43 - 115 U/L Female 0 to < 15 days : 76-233 U/L 15 days to < 1 year : 76 - 443 U/L 1 to 9 years : 132 - 315 U/L 10 to 12 years : 119 - 393 U/L 13 to 14 years : 107 - 442 U/L 15 to 16 years : 75 - 312 U/L	p-Nitro-phenylphosphate	5 ml Plain	1

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)																						
		17 to 18 years : 49 - 139 U/L ≥19 years : 33 - 98 U/L																									
ALPB	Alkaline Phosphatase - Bone (BAP)	5.1 - 20.2 ug/L	CLIA	5 ml Plain, <i>Separate serum and freeze</i>	5-7																						
ALPE	Alkaline Phosphatase Isoenzymes Electrophoresis - Liver, Bone, Intestine, Fast Liver	<table><tr><td>Category</td><td>Women</td><td>Men</td><td>Children (2-18 years)</td></tr><tr><td>L1 (Liver)</td><td>18-72%</td><td>15-71%</td><td>1-31%</td></tr><tr><td>L2 (Fast liver)</td><td>1-14%</td><td>1-9%</td><td>1-7%</td></tr><tr><td>B (Bone)</td><td>20-74%</td><td>23-75%</td><td>62-100%</td></tr><tr><td>I1 (Intestine 1)</td><td colspan="3" rowspan="3">These are not present in approximately 60% of healthy individuals. When present, levels do not exceed 14%.</td></tr><tr><td>I2 (Intestine 2)</td></tr><tr><td>I3 (Intestine 3)</td></tr></table>	Category	Women	Men	Children (2-18 years)	L1 (Liver)	18-72%	15-71%	1-31%	L2 (Fast liver)	1-14%	1-9%	1-7%	B (Bone)	20-74%	23-75%	62-100%	I1 (Intestine 1)	These are not present in approximately 60% of healthy individuals. When present, levels do not exceed 14%.			I2 (Intestine 2)	I3 (Intestine 3)	Electrophoresis	5 ml Plain	7-14
Category	Women	Men	Children (2-18 years)																								
L1 (Liver)	18-72%	15-71%	1-31%																								
L2 (Fast liver)	1-14%	1-9%	1-7%																								
B (Bone)	20-74%	23-75%	62-100%																								
I1 (Intestine 1)	These are not present in approximately 60% of healthy individuals. When present, levels do not exceed 14%.																										
I2 (Intestine 2)																											
I3 (Intestine 3)																											
	Allergy Tests (refer to Allergy Section in Profile Tests)																										
A1A	Alpha-1 Antitrypsin	90 -200 mg/g	Nephelometry	5 ml Plain	7																						
A1AS	Alpha-1 Antitrypsin, Stool	0-2.957 mg/g of dry stool	Radial Immunodiffusion	Fresh Stool	15																						
AFP	Alpha-Fetoprotein (AFP)	<9.0 ng/ml	CLIA	5 ml Plain	2																						
AMOE	Amoebic Antibody (<i>E histolytica</i>)	<9 (-); 9~11(+/-); > 11(+)NTU	ELISA	5 ml Plain	7																						
AMY	Amylase	28 – 100 U/L	CNPG3	5 ml Plain	2																						
ASD	Androstenedione (ASD)	Male (Age 20-67) : 0.64 – 2.97 ng/mL Female (Age 19-62) : 0.35 – 2.78 ng/mL PostMenopause : 0.30 – 2.07 ng/mL	RIA (Radioimmunoassay)	5 ml Plain, <i>Separate serum and freeze</i>	15																						
ABMZ	Anti-Basement Membrane Zone Abs (Anti-BMZ)	<1:10X(-)	IFA	5 ml Plain	15																						
ABGPG	Anti Beta-2 Glycoprotein-I IgG	Neg: <7.0; Equi: 7.0-10.0; Pos: >10.0 Elia IU/ml	CLIA	5 ml Plain	7-10																						

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
ABGPM	Anti Beta-2 Glycoprotein-I IgM	Neg: <7.0; Equi: 7.0-10.0; Pos: >10.0 Elia IU/ml	CLIA	5 ml Plain	7-10
ACAG	Anti-Cardiolipin IgG (ACA IgG) (a type of Antiphospholipid Ab)	Neg:<10.0; Equi:10.0-40.0; Pos: >40.0 GPL-U/ml	CLIA	5 ml Plain	8
ACAM	Anti-Cardiolipin IgM (ACA IgM) (a type of Antiphospholipid Ab)	Neg:<10.0; Equi:10.0-40.0; Pos: >40.0 GPL-U/ml	CLIA	5 ml Plain	8
ACCP	Anti-Cyclic Citrullinated Peptide Ab (Anti-CCP)	Neg: <35, Pos: >35 U/ml	Immunoturbidimetric	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	5
ADNA	Anti-double-stranded DNA (Anti-dsDNA)	<100 IU/mL	IFA	5 ml Plain	7
ENAT	Anti-Extractable Nuclear Antigen (Anti-ENA), Total (Qualitative)	<0.7(-) ; 0.7-1.0 (+/-) ; >1.0(+)	FLISA	5 ml Plain	7
ENA	Anti-ENA Identification (6 types): RNP Ab, Sm Ab, SS-5 ml Plain A Ab, SS-B Ab, Scl-70 Ab, & Jo-1 Ab	Anti-Ro Ab; SSA Neg: <7.0; Equivocal: 7.0-10.0; Pos: >10.0 Elia U/mL Anti-La Ab; SSB Neg: <7.0; Equivocal: 7.0-10.0; Pos: >10.0 Elia U/mL Anti-Smith Ab	SAT (Signal Amplification Technique)	5 ml Plain	

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
		Neg: <7.0; Equivocal: 7.0-10.0; Pos: >10.0 EliA U/mL RNP Ab Neg: <5.0; Equivocal: 5.0-10.0; Pos: >10.0 EliA U/mL JO1K5 Anti-JO-1 Neg: <7.0; Equivocal: 7.0-10.0; Pos: >10.0 EliA U/mL Scl-70 Ab Neg: <7.0; Equivocal: 7.0-10.0; Pos: >10.0 EliA U/mL			
GPCA	Anti-Gastric Parietal Cell Abs (APCA)	<1:10X(-)	IFA	5 ml Plain	7-14
GBM	Anti-Glomerular Basement Membrane Abs (AntiGBM)	<1:10X(-)	IFA	5 ml Plain	7-14
INTAB	Anti-Intercellular Substance Abs	<1:10X(-)	IFA	5 ml Plain	7-14
AMIA	Anti-Mitochondrial Ab	<1:40X(-)	IFA	5 ml Plain	12
AMH	Anti-Mullerian Hormone (AMH)	Ovarian Reserve: Very low <1.5pmol/L Low:<1.5-6.5 pmol/L Normal: 6.5-9.8pmol/L Good: > 19.8 pmol/L Ovarian Stimulation Response: Poor Response: <14.3pmol/L	CLIA	5 ml Plain	5-7

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
		High/Excessive: >22.8pmol/L PCOS SUSPECTED >52pmol/L			
ANCA	Anti-Neutrophil Cytoplasmic Ab (ANCA) with pattern (by IFA method)	Negative	IFA	5 ml Plain	12
ANA	Anti-Nuclear Abs (ANA) with pattern (by IFA)	Negative(<1:80)	IFA	5 ml Plain	5
APSG	Anti-Phosphatidylserine IgG	<12(-)	ELISA	5 ml Plain	7-10
ASMA	Anti-Smooth Muscle Ab (ASMA)	<1:40X(-)	IFA	5 ml Plain	12
ASA	Anti-Sperm Ab, Circulating	<150 mU/100µL	ELISA	5 ml Plain	7-10
ASOT	Anti-Streptolysin O Titre (ASOT), Spot test	Non-Reactive	latex agglutination	5 ml Plain	2
AT3	Anti-Thrombin III	83~128 %	Colorimetric method	2x 2 ml Citrate <i>Always specify the treatment and clinical context of the test prescription: Unfractionated heparin may induce a weak decrease in antitrombin level.</i>	15-20
ATAB	Anti-Thyroglobulin Ab (ATA)	<4 IU/mL	2 steps EIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	5
ATPO	Anti-Thyroid Peroxidase (Anti-TPO) / Anti-microsomal Ab	<9 IU/mL	2 steps EIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	5
APOA	Apolipoprotein A1 (Apo-A1)	M: 1.05-1.75g/L F: 1.05-2.05g/L	Immunoturbidimetric	5 ml Plain	3

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
APOB	Apolipoprotein B (Apo-B)	M: 0.60-1.40g/L F: 0.55-1.30g/L	Immunoturbidimetric	5 ml Plain	3
APOP	Apo- A1, Apo-B & Ratio	M: Risk: Average 0.7 - 0.9, High > 0.9 F: Risk: Average 0.6 - 0.8, High > 0.8	Calculation	5 ml Plain <i>Fasting sample.</i>	3
APOEG	Apolipoprotein E genotyping (by PCR)	Not Detected	PCR	5 ml Plain	7-14
AST	Aspartate Aminotransferase (AST/SGOT)	M: <50U/L F: <35U/L	P5P with UV	5 ml Plain	1
BJP	Bence-Jones Protein (by heat test) (consider Immunofixation Ep)	Negative	Thermal Turbidity	20 ml FMU, <i>Refrigeration, without preservatives and acid</i>	5
B2M	Beta-2 Microglobulin, Serum	0.97-1.84 mg/L	Immunoturbidimetric	5 ml Plain, <i>Always indicated the beginning or end of dialysis</i>	5
UB2M	Beta-2-Microglobulin, Urine	< 320ug/mL	Immunoturbidimetric	20 ml FMU	5
HCG	Beta-Human Chorionic Gonadotropin, Total (β-hCG)	Males: 0.1 - 1.0 IU/L Female: Non-Pregnant: < 5 mIU/mL Early Pregnancy: 5 - 25 mIU/mL Post-Menopause: 0.1 - 11.6 mIU/mL	CLIA	5 ml Plain	2
HCGF	β-hCG, Free	< 0.16 ng/mL	Kinetic Chemiluminescence	5 ml Plain	7
BID	Bilirubin, Direct/Conjugated *	<3.4 umol/L	DCP-TFB	5 ml Plain, <i>Wrap or Store away from light.</i>	1
BIT	Bilirubin, Total *	5-21 umol/L	DCP-TFB	5 ml Plain, <i>Wrap or Store away from light.</i>	1
	Blood Culture & Sensitivity (refer to Culture)				

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
ABORH	Blood Grouping & Rhesus (ABO & Rh)	-	Imunohaematology assay microplate & Tube method	3 ml EDTA	1
BRCA	BRCA 1 & 2 Gene Mutation Analysis Genetic risk marker for breast & ovarian cancer		(Pathogenic/Likely pathogenic mutation)	2x 3 ml EDTA <i>Attach the current clinical and therapeutic data</i>	14
BNPF	B-type Natriuretic Peptide (NT pro-BNP)	<300 pg/ml	FIA	3 ml EDTA (Plasma)	5
125	CA 125 (Ovarian cancer)	< 35 U/ml	CLIA	5 ml Plain	2
153	CA 15-3 (Breast cancer)	<23.5 U/ml	CLIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	2
199	CA 19-9 (Pancreatic, gastric cancer)	<35 U/ml	CLIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	5
724	CA 72-4 (TAG-72) (Gastrointestinal, Breast cancer)	<10.0 U/ml	CLIA	5 ml Plain <i>Collect the sample away from a meal to avoid hypergastrinemia. In case of proton pump treatment, recommended to collect the sample afstopsake. Or please collect the sample 2 weeks after treatment stopped. Separate serum & freeze.</i>	6-8
CAC	Calcitonin	M: <18.2 pg/ml F: <11.5 pg/ml	CLIA	5 ml Plain	7
CA	Calcium	2.20-2.65 mmol/L	Arsenazo III	5 ml Plain	1
CAF	Calcium, Free (Ionised)	1.15-1.35 mmol/L		5 ml Heparin (whole blood)	7-14

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
UCA	Calcium, Urine	100-300mg/24hrs	Arsenazo	24 hr Urine, <i>in an Acid preservative and Refrigeration</i>	5
CAD	Candida albicans DNA (by PCR)	Not Detected	PCR	Genital Swab / FVU	7
CEA	Carcino-Embryonic Antigen (CEA)	<5.0ng/ml (Non-Smoker) <10.0 ng/ml (Smoker)	CLIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	2
CARNI	Carnitine, Free & Total			5 ml Plain	14-20
CD48	CD4 / CD8 Count			3 ml EDTA Call Lab	5
CER	Ceruloplasmin	200.0-600.0 mg/L	Immunoturbidimetric	5 ml Plain	5
CHIM	Chikungunya IgM	Non-Reactive	RTK	5 ml Plain	2
CHO	Cholesterol, Total	Desirable: < 5.2 mmol/L	CHO-POD	5 ml Plain	1
CLPM	Chlamydia pneumoniae IgM	<1.4(-); 1.4-1.5(+/-); >1.5(+)	ELISA	5 ml Plain	7-10
CLA	Chlamydia trachomatis IgA	<5 (-); ≥5 - < 6(+/-); ≥ 6(+)	CLIA	5 ml Plain	5
CLG	Chlamydia trachomatis IgG	Negative: <1.0, Positive: ≥1.0	ELISA	5 ml Plain	5
CLM	Chlamydia trachomatis IgM	(-): <0.8 (+/-): ≥0.8-1.1 (+): >1.1	ELISA	5 ml Plain	5
CTNG	Chlamydia trachomatis & Neisseria gonorrhoeae DNA (by PCR)	Not Detected	PCR	Genital Swab / FVU	5
CGA	Chromogranin A (CgA)	< 101.9 ng/ mL	Automated Immunofluorescent Assay	5 ml Plain <i>Centrifuge without delay, separate the supernatant and freeze. PPIs should be stopped 2-3 weeks before the test.</i>	7-10
COOD	Coombs test, Direct	Negative	Agglutination	3 mL EDTA	7
CORT	Cortisol	8am : 184.85-623.5 nmol/L	CLIA	5 ml Plain	5

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)																											
		4pm : <275.9 nmol/L																														
CRE	Creatinine	Male : 59 -104 umol/L Female : 45 - 84 umol/L	Jaffe	5 ml Plain	1																											
DDI	D-Dimer (Quantitative) (may also consider FDP)	<0.5 mg/L	FIA	2 ml Citrate	5																											
DHEAS	Dehydroepiandrosterone Sulfate (DHEA-S)	Reference Values for DHEA-S (ug/dL) (CLIA method) <table><tr><td></td><td>Male</td><td>Female</td></tr><tr><td>Age</td><td>Range</td><td>Range</td></tr><tr><td>18 – 20</td><td>24 – 357</td><td>51 – 321</td></tr><tr><td>21 – 30</td><td>85 – 690</td><td>18 – 391</td></tr><tr><td>31 – 40</td><td>106 – 464</td><td>23 – 266</td></tr><tr><td>41 – 50</td><td>70 – 495</td><td>19 – 231</td></tr><tr><td>51 – 60</td><td>38 – 313</td><td>8 – 188</td></tr><tr><td>61 – 70</td><td>24 – 244</td><td>12 – 133</td></tr><tr><td>71 – 85</td><td>5 – 253</td><td>7 – 177</td></tr></table>		Male	Female	Age	Range	Range	18 – 20	24 – 357	51 – 321	21 – 30	85 – 690	18 – 391	31 – 40	106 – 464	23 – 266	41 – 50	70 – 495	19 – 231	51 – 60	38 – 313	8 – 188	61 – 70	24 – 244	12 – 133	71 – 85	5 – 253	7 – 177	CLIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	7
	Male	Female																														
Age	Range	Range																														
18 – 20	24 – 357	51 – 321																														
21 – 30	85 – 690	18 – 391																														
31 – 40	106 – 464	23 – 266																														
41 – 50	70 – 495	19 – 231																														
51 – 60	38 – 313	8 – 188																														
61 – 70	24 – 244	12 – 133																														
71 – 85	5 – 253	7 – 177																														
DENGM	Dengue Serology (IgG & IgM), Rapid Test	Non-Reactive	RTK	5 ml Plain	1																											
DENAG	Dengue NS1 Antigen (intended for 1st -5th days)	Non-Reactive	RTK	5ml plain	1																											
DHT	Dihydrotestosterone (DHT)	Male (pg/mL) (1-9) <17.0-85.7 (10-14) <17.0-875.6 (15-18) 70.3-1260.9 (20-89) 143.0-842.0 Female (pg/mL) (2-9) <17.0-88.9 (10-14) 22.5-280.6 (15-18) 62.6-760.3 (18-50) <17.0-596.0 (51-83) <17.0-431.0	ELISA	5 ml Plain <i>Separate serum & freeze.</i>	7-10																											
DNAF	DNA Profiling for Paternity (for non-legal proceedings only)	Referral		3 ml EDTA <i>Specimen each from child, mother & alleged father. Use Specific Form</i>	14																											
	Down Syndrome Screen (refer to Foetal Screen in Profile Test)																															
ELT	Electrolytes (Na, K & Cl), Serum	Na: 136-146 mmol/L K:3.5-5.1 mmol/L CL: 101-109mmol/L	Electrical Potential	5 ml Plain	1																											

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
UFLT	Electrolytes (Na, K & Cl), Urine	Na: 40-220mEq/24hrs K: 25-125mEq/24hrs CL: 110-250 mEq/24hrs	Electrical Potential	24 hr Urine, <i>in Refrigeration without acid preservative</i>	1
ELAL	Endotoxin, LAL Assay	<0.25 EU/mL	Gel method	Water/ Dialysate	7
ECP	Eosinophil Cationic Protein (ECP)	≤13.3 ug/L	Fluoro Enzyme Immunoassay	5 ml Plain	5
EBVD	Epstein-Barr virus (EBV) DNA Detection	Not Detected	PCR	Serum/ Swab/ Fluid	7
EBA	EBV EA+NA1 IgA (for NPC)	<4.5 EU/mL (+) 4.5-6.0 EU/mL (+/-) >6.0 EU/mL (+)	ELISA	5 ml Pain	5
EBEG	EBV Early Ag (EA) IgG (for IM/NPC)	<100 AU/mL (-) 100-120 AU/mL(+/-) >120 AU/mL(+)	SAT METHOD	5 ml Plain	5
EBVA	EBV Viral Capsid Ag (VCA) IgA (for NPC)	Non-Reactive: <1.0; Reactive: ≥1.0	ELISA	5 ml Plain	3
EBVG	EBV Viral Capsid Ag (VCA) IgG (for IM)	≤0.90(-); 0.91-1.09 (±); ≥1.1(+)	CLEIA	5 ml Plain	8
EBVM	EBV Viral Capsid Ag (VCA) IgM (for IM)	≤0.90(-); 0.91-1.09 (±); ≥1.1(+)	CLEIA	5 ml Plain	8
ESR	Erythrocyte Sedimentation Rate (ESR)	M:0-15 mm/hour F:0-20 mm/hour	Westergren manual method	3 ml EDTA	1
EPO	Erythropoietin (EPO)	4.3-29.0 mIU/mL	CLIA	5 ml Plain, <i>Sample in morning (variations during day). Separate serum & freeze.</i>	7
E2	Estradiol (E2) (Ovarian Function)	pmol/L (Unit) Males: < 55.1 - 115.6 Early Follicular: 82.23 - 422.2 Mid-follicular phase: 91.8 - 422.2 Ovulatory Peak: 117.8 - 1897.9 Mid-luteal phase: 134 - 903.1 Post-menopausal (Not on Hormone Therapy): < 55.1 - 92.1	CLIA	5 ml Plain	3

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
E3U	Estriol, Free (uE3) (Pregnancy Monitoring)	Non-pregnant women: 0.017-0.066 ng/mL 18 weeks: 2.500-7.000 ng/mL 22 weeks: 3.800-11.000 ng/mL 29 weeks: 5.000-14.000 ng/mL 30 weeks: 5.500-15.500 ng/mL 32 weeks: 6.500-19.000 ng/mL 34 weeks: 7.800-25.000 ng/mL 36 weeks: 9.000-27.000 ng/mL 38 weeks: 13.000-34.500 ng/mL 40 weeks: 15.000-44.000 ng/mL	CLIA	5 ml Plain	7
FBC	Full Blood Count	Haemoglobin Birth 14.0-22.0 Day3 15.0-21.0 Day7 13.5-21.5 Day14 12.5-20.5 1Month 11.5-16.5 2Months 9.4-13.0 3-6Months 11.1-14.1 1 year 11.1-14.1 2-5 years 11.0-14.0 6-12 years 11.5-15.5 ≥13 years (F) 11.5 - 16.0 ≥13 years (M) 13.0 - 18.0 RBC (mil/cumm) Birth 5.0 - 7.0 Day3 4.0 - 6.6 Day7 3.9 - 6.3 Day14 3.9 - 6.2 1Month 3.0 - 5.4 2Months 3.1 - 4.3 3-6Months 4.1 - 5.3 1 year 3.9 - 5.1 2-12 years 4.0-5.2 ≥13 years (F) 3.8-5.8 ≥13 years (M) 4.5-6.5 HCT (%) Birth 45-75 Day 3 45-67 Day 7 42-66 Day 14 31-71 1 month 33-53 2 months 28-42 3-6 months 30-40	FBC analysis and VCSn analysis	3 mL EDTA	1

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
		1 year 30-38 2-5 years 34-40 6-12 years 35-45 ≥ 13 years (F) 35-47 ≥ 13 years (M) 40-54 MCV (fL) Birth 100-120 Day 3 92-118 Day 7 88-126 Day 14 86-124 1 month 92-116 2 months 87-103 3-6 months 68-84 1 year 72-84 2-5 years 75-87 6-12 years 77-95 ≥ 13 years 78-96 MCH (pg) Birth 31-37 Day 3 31-37 Day 7 31-37 Day 14 31-37 1 month 30-36 2 months 27-33 3-6 months 24-30 1 year 25-29 2-6 years 24-30 6-12 years 25-33 ≥ 13 years 27-33 MCHC (g/dL) Birth 30-36 Day 3 29-37 Day 7 28-38 Day 14 28-38 1 month 29-37 2 months 28.5-35.5 3-6 months 30-36 1 year 32-36 2-6 years 31-37 6-12 years 31-37 ≥ 13 years 30-37 RDW 11.0-16.0 %			

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
		Platelet (tho/cumm) Birth 100-450 Day 3 210-500 Day 7 160-500 Day 14 170-500 1 month 200-500 2 months 210-650 3-6 months 200-550 1 year 200-550 2-5 years 200-490 6-12 years 170-450 ≥ 13 years 150-400 WBC (tho/cumm) Birth 10-26 Day 3 7-23 Day 7 6-22 Day 14 6-22 1 month 5-19 2 months 5-15 3-6 months 6-18 1 year 6-16 2-6 years 5-15 6-12 years 5-13 ≥ 13 years 4-11 Neutrophils 40-75 % Lymphocyte 20-45% Monocyte 2-10% Eosinophils 1-6% Basophils 0-1%			
FBP	Full Blood Picture (Blood film comment)	-	Direct smear	3 ml EDTA	2
FOB	Faecal Occult Blood <i>(human-Hb specific)</i>	Non-Reactive	RTk	Fresh Stool	2
FFEM	Faeces FEME- <i>for Amoeba/Ova/Cyst</i>	No pus cells and No RBC seen.	-	Fresh Stool	2

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)						
		No Amoeba, Cyst or Ova seen.									
FER	Ferritin	Male: 23.9 - 336.2 pg/ml Female: 11.0 - 306.8 pg/ml	CLIA	5 ml Plain	5						
FHB	Foetal Haemoglobin (APT Test)			Stool/ Vomitus	5						
FDP	Fibrin Degradation Products (FDP) (may also consider D-Dimer)	<20 ug/ml	Immunoturbidimetry	2x 2 ml Citrate	2						
FIB	Fibrinogen	2.00-3.93 mg/dL	Coagulation	2x 2 ml Citrate	5						
FPAB	Filariasis Antibodies (IgG & IgM)	Negative	Rapid Chromatographic Immunoassay	5 mL Plain	1						
FOLR	Folic Acid (Folate), RBC			3 ml EDTA, <i>wrap and avoid light</i>	Research, Call						
FOL	Folic Acid (Folate), Serum	>5.9 ng/ml	CLIA	5 ml Plain, <i>Fasting sample.</i>	5						
FSH	Follicle Stimulating Hormone (FSH)	<table><tr><td>mIU/mL</td></tr><tr><td>Males: 1.27-19.26</td></tr><tr><td>Mid-Follicular Phase: 3.85-8.78</td></tr><tr><td>Mid-Cycle Peak: 4.54- 22.51</td></tr><tr><td>Mid-Luteal Phase: 1.79-5.12</td></tr><tr><td>Post-Menopausal: 16.74-113.59</td></tr></table>	mIU/mL	Males: 1.27-19.26	Mid-Follicular Phase: 3.85-8.78	Mid-Cycle Peak: 4.54- 22.51	Mid-Luteal Phase: 1.79-5.12	Post-Menopausal: 16.74-113.59	CLIA	5 ml Plain	5
mIU/mL											
Males: 1.27-19.26											
Mid-Follicular Phase: 3.85-8.78											
Mid-Cycle Peak: 4.54- 22.51											
Mid-Luteal Phase: 1.79-5.12											
Post-Menopausal: 16.74-113.59											
FXSG	Fragile X Syndrome (FXS) Genetic Assay	-	PCR	3 ml EDTA	14						
FRUC	Fructosamine	<285 umol/L		5 ml Plain	Research, Call						
FUNG	Fungus Microscopic	Not Seen		Skin Scraps	2						
G6PD	G6PD Screening	Normal	Rapid fluorescent spot test	Blotted blood on paper or 3 ml EDTA	2						
G6PQ	G6PD, Quantitative	7.9-16.3 U/g Hb	NADPH	3 ml EDTA	3-5						
GGT	Gamma-Glutamyl Transferase (GGT)	M: <55 U/L F: < 38 U/L	Gamma glutamyltransferase	5 ml Plain	1						
GAS	Gastrin	13-115 pg/ml	CLIA	5 ml Plain, <i>Fasting minimum 10 – 12 hours. After removing the coagulated mass, quickly</i>	7						

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
				<i>centrifuge the sample to separate the serum & freeze.</i>	
GLU	Glucose, Fasting	Normal: <6.1 mmol/L Impaired: 6.1-6.9 mmol/L Diabetes: >7.0 mmol/L	Hexokinase	2 ml Fluoride, <i>Fasting</i>	1
GLU2	Glucose, 2 hrs Post-Glucose Load	Normal: 4.0 - 7.8 mmol/L Impaired: 7.9 - 11.0 mmol/L Diabetic: >11.0 mmol/L	Hexokinase	2x 2 ml Fluoride, <i>Fasting & 2 hours Post-Glucose</i>	1
GAD	Glutamic Acid Decarboxylase AutoAbs (GAD AutoAbs)	<5 U/mL	ELISA	5 ml Plain	15-20
GALB	Glycated Albumin (GA) (diabetic monitoring)	11 - 16 %	Enzymatic	5 ml Plain	3 -5
GRAM	Gram's Stain Examination	Not Seen	-	Swab / Smear / Urine	1
HGH	Growth Hormone (hGH)	<6.6 ng/mL	RIA	5 ml Plain Separate serum & freeze. Note time of collection & fasting / stimulation / suppression	7
A1C	Haemoglobin A1c (HbA1c)	Normal: <5.6 % Pre-diabetes: 5.6-6.2 % Diabetes: >6.3 % Control Target: <6.5	Turbidimetric immunoinhibition	3 ml EDTA Shortened red blood cell survival, accelerated turnover (e.g., recovery from blood loss), or haemolytic anaemia will falsely lower results.	1
HAPG	Haptoglobin	44-215 mg/dL	Immunoturbidimetric	5 ml Plain	5
HDLC	HDL-Cholesterol (Direct Method)	Male : >1.00 mmol/L Female : >1.20 mmol/L	Accelerator Selective Detergent	5 ml Plain	1
HPYG	H. pylori IgG (semi-quantitative)	Non-Reactive: <1.000, Reactive: >= 1.000	CLIA	5 ml Plain	2
HPYA	H. pylori Abs (with Current Infection Marker)	Non-Reactive	colloidal gold	5 ml Plain	2
UBT4	H. pylori 14C-Urea Breath Test	Negative	Urea Breath	Breath in card Resting patient, fasting for a minimum of 6 hours (no drink, no food, no smoke). No antibiotic treatment for 4 weeks. No Proton-pump inhibitor	3

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
				treatment for 2 weeks. No antacids and gastro-intestinal protectants 24 hours before the test.	
HAV	Hepatitis A IgG (Anti-HAV)	Reactive: Immunity	CLIA	5 ml Plain	1
AVM	Hepatitis A IgM (HAV IgM)	Negative: <1.0	ECLIA	5 ml Plain	5
BCG	Hepatitis B core Abs (Anti-HBc)	Negative: <1.0	ECLIA	5 ml Plain	5
BCM	Hepatitis B core IgM (HBc IgM)	Negative: <1.0	ECLIA	5 ml Plain	5
BCAG	Hepatitis B core-related Antigen (HBcr Ag), Quantitative	<3 LogU/mL	CLEIA	5 ml Plain	7-10
EAB	Hepatitis B envelope Ab (Anti-HBe)	Reactive	CLIA	5 ml Plain	3
EAG	Hepatitis B envelope Ag (Hbe-Ag)	Non-Reactive	CLIA	5 ml Plain	3
SAB	Hepatitis B surface Ab (Anti-HBs)	Non-Reactive:<10mIU/mL Strong immunity:>100mIU/mL	CLIA	5 ml Plain	1
SAG	Hepatitis B surface Ag (HBs-Ag)	Non-Reactive	CLIA	5 ml Plain	1
SAGQ	Hepatitis B surface Ag, Quantitative	<0.005 IU/mL	CLIA	5 ml Plain	5
HBVPC	HBV Pre-core (PreC) Mutant	Non-mutate	Real-time PCR	5 ml EDTA (Plasma), Separate plasma & freeze	7-14
HBVPS	HBV Pre-surface (PreS) Mutant	Non-mutate	Real-time PCR	5 ml EDTA (Plasma), Separate plasma & freeze	7-14
HBVY	HBV Drug Resistance Analysis	Non-mutate	DNA analysis	5 ml EDTA (Plasma), Separate plasma & freeze. Please specify the date and result of the last viral load. The minimum viral load is 100 IU.	14
HBVG	HBV-DNA Genotyping	Undetected	PCR	5 ml EDTA (Plasma), Separate plasma & freeze. Please specify the date and result of the last viral load. The minimum viral load is 100 IU.	14
HBVL	HBV-DNA Viral load (by qPCR)	Not Detected	Real-time PCR	5 ml EDTA (Plasma), Separate plasma & refrigerate	7-10

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
HCV	HCV Antibody (CLIA)	Non-Reactive	CLIA	5 ml Plain	2
HCVA	HCV Antibody (ELISA)	Non-Reactive	ELISA	5 ml Plain	2
HCVG	HCV-RNA Genotyping	Undetected	Real time PCR	5 ml EDTA (Plasma), Separate plasma & freeze. Please specify the date and result of the last viral load. The minimum viral load is 500 IU.	7-14
HCVR	HCV-RNA Viral load (qPCR)	<10 IU/mL (Not Detected)	Real-time PCR	3 ml EDTA (Plasma), Separate plasma & refrigerate	7-10
H1G	Herpes Simplex Virus (HSV) Type 1 IgG	Negative: <1.0, Positive: ≥1.0	ELISA	5 ml Plain	5
H2G	HSV Type 2 IgG	Negative: <1.0, Positive: ≥1.0	ELISA	5 ml Plain	5
H12M	HSV Type 1 & 2 IgM	Index <0.9 (-) ≥0.9 to <1.1 (+/-) ≥1.1 (+)	ELISA	5 ml Plain	5
HSVD	HSV DNA type 1 & 2 DNA	Not Detected	PCR	Swab/ Urine/ CSF/ Serum	7-14
HCY	Homocysteine, total (tHcy)	5.0-15.0 umol/L	Enzymatic assay	3 ml Plain, Fasting, refrigerated, separate serum a.s.a.p	3
HVA	Homovanillic Acid (HVA)	3.00 - 8.00 mg/day	HPLC	24 hr Urine, in Acid preservative and Refrigeration	5-7
HIV	Human Immunodeficiency Virus (HIV) (HIV 1&2 Ab+p24 Ag)	Non-Reactive	CLIA	5 ml Plain Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.	2
HIVCT	HIV 1 & 2 Confirmation Test (ICA) - identify both type 1 & 2	Negative	Immunochromatographic (ICT)	5 ml Plain	7
HIVL	HIV-RNA Viral load (RT-PCR)	< 20.0 Copies/mL	Real time PCR	2x 3 ml EDTA (Plasma), Separate plasma & refrigerate	7
HLA12	Human Leukocyte Ag (HLA) Typing (by NGS) Total 12 loci – HLA-A, B, C, DRB1,	-	PCR	3 ml EDTA	20-30

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
	DQB1, DPB1, DPA1, DQA1, DRB3/4/5 & G				
HLAA	HLA Typing – HLA-A	-	PCR	3 ml EDTA	14-18
HLAB	HLA Typing – HLA-B	-	PCR	3 ml EDTA	14-18
HLAC	HLA Typing – HLA-C	-	PCR	3 ml EDTA	14-18
HLARB	HLA Typing – HLA-DRB1	-	PCR	3 ml EDTA	14-18
HLAQB	HLA Typing – HLA-DQB1	-	PCR	3 ml EDTA	14-18
HLAPB	HLA Typing – HLA-DPB1	-	PCR	3 ml EDTA	14-18
HCRP	High sensitive C-Reactive Protein	CVD Risk Low: <1.0, High: >3.0 Inflammation: >10	Immune-turbidimetric	5 ml Plain	1
B27	Human Leukocyte Ag (HLA) -B27 Genes	Negative	PCR	3 ml EDTA	14-18
B1502	Human Leukocyte Ag (HLA) -B1502 Genes	Negative	PCR	3 ml EDTA	14-18
B5801	Human Leukocyte Ag (HLA) -B5801 Genes	Negative	PCR	3 ml EDTA	14-18
HPVD	Human Papilloma Virus (HPV) DNA Genotyping - detect & report 32 major high & low risk genotypes	Not detected	PCR	Cervical Brush in collection kit	7
HPVS	Human Papilloma Virus (HPV) DNA Screen – detect 16, 18 and 13 other high-risk genotypes	Not detected	PCR	Cervical Brush in collection kit	7-10
HDGA	Huntington's Disease Genetic Assay	Normal	PCR	3 ml EDTA	7-14
IFE	Immunofixation Electrophoresis (IFE), Serum	No paraprotein	Electrophoresis	5 ml Plain	14
IFEU	Immunofixation Electrophoresis (IFE), Urine/CSF	No paraprotein	Electrophoresis	50 ml FMU or 24hr Urine/10 ml CSF	14
IGA	Immunoglobulin A (IgA)	66-433 mg/dL	Immunoturbidimetric	5 ml Plain	5
IGD	Immunoglobulin D (IgD)	<132.1 mg/L	SRID	5 ml Plain	8

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
IGE	Immunoglobulin E (IgE), Total	<100 kU/L	CLIA	5 ml Plain	5
IGEC	Immunoglobulin E (IgE), Low Range (for Newborn)	Cordblood : < 0.90kU/L	CLIA	3 ml EDTA Cord Blood (Plasma)	5
IGG	Immunoglobulin G (IgG)	635-1741 mg/dL	Immunoturbidimetric	5 ml Plain	5
IGGS	Immunoglobulin G Subclass 1 - 4		Nephelometry	5 ml Plain	10
IGM	Immunoglobulin M (IgM)	45-281 mg/dL	Immunoturbidimetric	5 ml Plain	5
INAB	Influenza Virus type A & B Antigen - Rapid	Negative	RTK	Nasopharyngeal Swab	1
INHA	Inhibin A	Female - Normal cycling women (days relative to LH surge peak) Early follicular phase (Day -14 to -10) : 1.8 – 17.3 pg/mL Mid follicular phase (Day -9 to -4) : 3.5 – 31.7 pg/mL Late follicular phase (Day -3 to -1) : 9.8 – 90.3 pg/mL Mid-cycle (Day 0, LH surge peak) : 16.9 – 91.8 pg/mL Early luteal phase (Day +1 to +3) : 16.1 – 97.5 pg/mL Mid luteal phase (Day +4 to +11) : 3.9 – 87.7 pg/mL Late luteal phase (Day +12 to +14) : 2.7 – 47.1 pg/mL Postmenopausal : < 2.1 pg/mL Male : < 2.0 pg/mL	CLIA	5 ml Plain	7
INS	Insulin	1.9-23.0 uIU/mL	CLIA	5 ml Plain, Fasting sample. Separate serum & freeze. For HOMA index calculation, confirm the fasting blood sugar level performed on the same day as the sample collection for insulin. Interference possible in patients treated with biotin (vitamin	5

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
				<i>B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample</i>	
IGF1	Insulin-like Growth Factor-1 (IGF-1), Total (Somatomedin-C)	Biological Reference Interval	CLIA	5 ml Plain (fasting), Separate serum & freeze.	7
		Age Range (ng/mL)			
		1 56 – 344			
		2 50 – 300			
		3 49 – 311			
		4 53 – 307			
		5 55 – 305			
		6 54 – 306			
		7 57 – 312			
		8 64 - 358			
		9 73 – 385			
		10 88 – 463			
		11 111 - 549			
		12 143 – 686			
		13 183 - 859			
		14 220 – 972			
		15 235 – 988			
		16 226 – 938			
		17 193 – 754			
		18 163 – 579			
		19 143 – 486			
		20 128 – 464			
		21-25 138 – 363			
		26-30 116 – 334			
		31-35 115 – 320			
		36-40 111 – 284			
		41-45 101 – 270			
		46-50 94 – 266			
		51-55 87 – 234			
		56-60 85 – 230			
		61-65 75 – 223			

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
		66-70 69 – 211			
		71-75 64 – 188			
		76-80 59 – 181			
		81-85 49 – 161			
SI	Iron, Serum	M:12.5-32.2umol/L F:10.7-32.2umol/L	TPTZ	5 ml Plain, Fasting sample.	1
IA2	Islet Antigen-2 (IA2) Antibodies	<7.5 u/mL	ELISA	5 ml Plain, Separate serum & freeze.	30
LCA	Lactate (Lactic Acid), plasma	0.5-2.2 mmol/L	Enzymatic	3 ml Fluoride, fasting, avoid tourniquet	5
LDH	Lactate Dehydrogenase (LDH)	<248U/L	Lactate-Pyruvate (NAD)	5 ml Plain	1
LDHE	LDH Isoenzyme Electrophoresis	LDH 1 : 16.1 - 31.5 % LDH 2 : 29.2 - 41.6 % LDH 3 : 17.0 - 26.2 % LDH 4 : 5.9 - 12.3 % LDH 5 : 3.2 - 17.3 %	Electrophoresis	5 ml Plain	5
LDL1	LDL-Cholesterol (Direct Method)	<2.60 mmol/L	CHO-POD	5 ml Plain	1
LEG	Legionella Antibodies	<1:128X (-)	IFA	5 ml Plain	7-10
LEGUG	Legionella Urinary Antigen	Negative	Immunochromatographic (ICT)	20 ml Urine	5
	Leptin			5 ml Plain	Research, call
LPSM	Leptospira IgM	Non-Reactive	RTK	5 ml Plain	3
LIPA	Lipase	11-82 U/L	Enzymatic, Colorimetric	5 ml Plain	5
LPA	Lipoprotein (a), Lp(a)	<75 nmol/L	Latex immunoturbidimetric	5 ml Plain	5
LEP	Lipoprotein Electrophoresis	Alpha lipoproteins (HDL): 22.3-53.3% Pre-beta lipoproteins (VLDL): 4.4-23.1% Beta lipoproteins (LDL): 38.6-69.4%	Electrophoresis	5 ml Plain	5

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)						
LUPA	Lupus Anticoagulant (by PTT-LA & dRVVT)	Negative	STACLOT_LA	2x 2* ml Citrate *as specified on tube, Stop heparin therapy one day before test. (freeze Plasma)	5-7						
LH	Luteinising Hormone (LH)	<table><tr><td>mIU/ml</td></tr><tr><td>Males: 1.24-8.62</td></tr><tr><td>Mid-Follicular Phase: 2.12-10.89</td></tr><tr><td>Mid-Cycle Peak: 19.18-103.03</td></tr><tr><td>Mid-Luteal Phase: 1.20-12.86</td></tr><tr><td>Post Menopausal: 10.87-58</td></tr></table>	mIU/ml	Males: 1.24-8.62	Mid-Follicular Phase: 2.12-10.89	Mid-Cycle Peak: 19.18-103.03	Mid-Luteal Phase: 1.20-12.86	Post Menopausal: 10.87-58	CLIA	5 ml Plain	3
mIU/ml											
Males: 1.24-8.62											
Mid-Follicular Phase: 2.12-10.89											
Mid-Cycle Peak: 19.18-103.03											
Mid-Luteal Phase: 1.20-12.86											
Post Menopausal: 10.87-58											
MGS	Magnesium, Serum	M: 0.73-1.06 mmol/L F: 0.77-1.03 mmol/L	Xylidyl Blue	5 ml Plain	2						
MALA	Malaria Parasite	Not Seen	Direct smear	3 ml EDTA	2						
MPAG	Malaria Antigen	Non-Reactive	ELISA	3 ml EDTA	2						
MEAG	Measles IgG	(-): <13.5, (+/-): 13.5-16.5, (+): >16.5 AU/mL	ELISA	5 ml Plain	7						
MEAM	Measles IgM	<0.8(-); ≥0.8-<1.1(+/-); ≥1.1(+)	ELISA	5 ml Plain	7						
MTHFR	Methylenetetrahydrofolate reductase (MTHFR) Genetic Assay	-	PCR	3 ml EDTA	7-14						
MFP	Microfilaria Parasite	Not seen	Direct smear	3 ml EDTA	2						
MON	Monospot (Infectious Mononucleosis) (may also consider EBV)	Non-Reactive		5 ml Plain	1						
MUMG	Mumps IgG	<9.0(-); ≥9.0 to <11.0(+/-); ≥11.0 (+) AU/mL	ELISA	5 ml Plain	8						
MUMM	Mumps IgM	<0.8(-); ≥0.8-<1.1(+/-); ≥1.1(+)	ELISA	5 ml Plain	8						
TBGXP	TB Rapid Gene Xpert PCR	Not Detected	PCR	Sputum	2						

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)												
TBIGRA	TB- Interferon Gamma Release Assay (TB-IGRA) (QuantiFERON)	Negative	QuantiFeron	5 ml Heparin Blood, reach lab within 2hrs In room temperation, Call Lab	7												
MGEND	Mycoplasma genitalium DNA Detection	Not Detected	PCR	Plain Swab	7												
MHOMD	Mycoplasma hominis DNA Detection	Not Detected	PCR	Plain Swab	7												
MPG	Mycoplasma pneumoniae IgG	1:40X(-)	Particles Agglutination; PA	5 ml Plain	5												
MPM	Mycoplasma pneumoniae IgM	<10.0 (-)	ELISA	5 ml Plain	7												
MYG	Myoglobin, serum	M: 17.4-105.7 ng/mL; F: 14.3-65.8 ng/mL	Chemiluminescence	5 ml Plain	5												
MYGU	Myoglobin, urine	<11.5 ng/mL	Chemiluminescence	20ML Urine bottle	5												
NSE	Neuron-Specific Enolase (NSE)	<20.0 ng/ml	CLIA	5 ml Plain. Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.	5												
OSS	Osmolality,Serum	275-295 mOsm/kg H2O	Freezing point depression method	5ml , Plain	5												
OSU	Osmolality, Urine	50-1200 mOsm/kg H2O	Freezing point depression method	20 ml Urine	5												
OTC	Osteocalcin	Male <table><tr><td colspan="2">Biological Reference Interval</td></tr><tr><td>Age Range</td><td>(ng/mL)</td></tr><tr><td>18-<30</td><td>24.00-70.00</td></tr><tr><td>30-50</td><td>14.00-42.00</td></tr><tr><td>>50-70</td><td>14.00-46.00</td></tr></table> Female <table><tr><td colspan="2">Biological Reference Interval</td></tr></table>	Biological Reference Interval		Age Range	(ng/mL)	18-<30	24.00-70.00	30-50	14.00-42.00	>50-70	14.00-46.00	Biological Reference Interval		ECLIA	3 ml EDTA (Plasma) fasting, morning	7
Biological Reference Interval																	
Age Range	(ng/mL)																
18-<30	24.00-70.00																
30-50	14.00-42.00																
>50-70	14.00-46.00																
Biological Reference Interval																	

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
		(ng/mL)			
		>20 years to pre menopause 11.00-43.00			
		Post menopause 15.00-46.00			
		Osteoporosis 13.00-48.00			
PAP	PAP Smear	Bethesda report format	Pap Stain	Fixed smear	4-6
PALP	PAP Test, Liquid based preparation	Bethesda report format	Pap Stain	Cervical brush in Collection kit	4-6
PTHl	Parathyroid Hormone, Intact (PTH-I)	1.3-9.3 pmol/L	CLIA	3 ml Plain/EDTA, <i>Fasting morning Separate serum/plasma a.s.a.p. & refrigerated.</i>	5-7
PB19D	Parvovirus B19 DNA (by PCR)	Not Detected	PCR	5 ml Plain Blood / CSF	7
PHOS	Phosphorus, Serum	0.81-1.45 mmol/L	Phospho-molybdate	5 ml Plain	1
UP	Phosphorus, Urine	Adult:300-1300 mg/24hrs Children:500-800mg/24hrs	Phosphomolybdate Complex	24 hr Urine, <i>in Acid preservative and Refrigeration</i>	5
PALB	Prealbumin	17-34 mg/dL	Immunoturbidimetric	5 ml Plain	5
PCT	Procalcitonin (PCT)	<0.046 ng/mL	ECLIA	5 ml Plain	7
P1NP	Procollagen 1 N-Propeptide (P1NP)	Pre-menopause: 15.13-58.59 ng/mL Post-menopause: 16.27-73.87ng/mL	-	5 ml EDTA (Plasma)	Research, call
PRG	Progesterone (P4)	(nmol/L) Males: 0.45 - 6.55 Mid-Follicular Phase: 0.99 - 4.83 Mid-Luteal Phase: 16.41 - 59.02 Post-Menopausal: < 0.25 - 2.48 1st Trimester: 15.04 - 161.35 2nd Trimester: 61.7 - 144.1	CLIA	5 ml Plain	5
PRL	Prolactin	(mIU/L)	CLIA	5 ml Plain	3

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)												
		Males: 2.64-13.13 Premenopausal: 3.34-26.72 Postmenopausal: 2.74-19.64															
PACND	Propionibacterium acnes DNA (by PCR)	Not Detected	PCR	Swab	7-14												
PSA	Prostatic Specific Antigen (PSA)	Males: 0.0-4.0 ng/mL	CLIA	5 ml Plain	2												
PSAF	Prostate Specific Ag, Free	0.200-4.900 ng/mL	CLIA	5 ml Plain	5												
PHI	Prostate Health Index (PSA, Fpsa, p2PSA)	<table><tr><td>PHI Value Range</td><td>Average Cancer Risk</td><td>Risk of Prostate Cancer with GS ≥ 7</td></tr><tr><td>< 25</td><td>5%</td><td>1.5%</td></tr><tr><td>25 - 35</td><td>7.5%</td><td>3.4%</td></tr><tr><td>35 - 55</td><td>26%</td><td>17%</td></tr></table>	PHI Value Range	Average Cancer Risk	Risk of Prostate Cancer with GS ≥ 7	< 25	5%	1.5%	25 - 35	7.5%	3.4%	35 - 55	26%	17%	CLIA	5 ml Plain	5
PHI Value Range	Average Cancer Risk	Risk of Prostate Cancer with GS ≥ 7															
< 25	5%	1.5%															
25 - 35	7.5%	3.4%															
35 - 55	26%	17%															
PROC	Protein C	70-140 %	colorimetric method	2x 2 ml Citrate <i>PC is vitamin K dependant and testing must be performed well after any AVK treatment (1 month). Do not assay in the event of ongoing treatment with a direct-acting oral anticoagulant. Separate plasma & freeze.</i>	15-20												
PROS	Protein S	63.5-149.0 %	coagulation method	2x 2 ml Citrate <i>PS is vitamin K dependant and testing must be performed well after any AVK treatment (1 month). Do not assay in the event of ongoing treatment with a direct-acting oral anticoagulant. Separate plasma & freeze.</i>	10-12												
PEP	Protein Electrophoresis, Serum	Albumin 55.8 - 66.1 % α-1 Globulin 2.9 - 4.9 % α-2 Globulin 7.1 - 11.8 % β1-Globulin 4.7 - 7.2 % β2-Globulin 3.2 - 6.5 % γ-Globulin 11.1 - 18.8 % M-Protein (%) 0 %	capillary electrophoresis	5ml Plain	5												

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
UPEP	Protein Electrophoresis, Urine	-	Gel electrophoresis	20 ml FMU	8-10
PRO	Protein, Serum	66-83 g/L	Biuret	5 ml Plain	1
UPRO 24UPR	Protein, Urine 24 hours Urine protein	Random <0.1 g/L; 0.05 – 0.08 g/24 hrs	Pyrogallol red	24 hr Urine, <i>in Refrigeration without acid preservative</i>	3
PT	Prothrombin Time (PT/INR)	<1.3, Therapeutic:2.0-3.0	Stago coagulation system	2 ml Citrate <i>Do not draw blood from a heparinized line. Avoid contaminating the sample with tissue thromboplastin or heparin. Venipuncture must be performed with no trauma. If blood is drawn from an indwelling catheter, flush with 5 mL of saline and discard the first 5 mL of blood collected. If blood is drawn with a butterfly device, draw a discard tube first to remove air from tubing.</i>	2
RENC	Renin Concentration, Total	Normal : 3.18 - 32.61 pg/mL Upright : 5.41 - 34.53 pg/mL Supine : 2.71 - 16.51 pg/mL	CLIA	3 ml EDTA (Plasma), <i>Separate plasma and refrigerate a.s.a.p. Specify patient's posture, upright or recumbent. Normal sodium intake & stop medication for 2 days</i>	7
	Resistin				Research, call
RSV	Respiratory Syncytial Virus (RSV) Ag	Non-Reactive	RTK	Nasopharyngeal Aspirates	7
RC	Reticulocyte Count	0.2 – 2.0%	Blood smear	3 ml EDTA	2
RF	Rheumatoid Factor (Quantitative)	<14.1 IU/mL	latex-enhanced immunoturbidimetric	5 ml Plain	2
ROMA	Risk of Ovarian Malignancy Algorithm (ROMA) (HE4 + CA-125)	Before Menopausal<7.4% After Menopausal<25.3%	CMIA	5 ml Plain <i>HE4 and CA125 must be assayed with the same technology. Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin.</i>	7-10

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
				<i>Essential to stop treatment 8 days before taking the sample.</i>	
ROTA	Rotavirus Antigen	Non-Reactive	RTK	Fresh Stool	2
RG	Rubella IgG	Immunity: >10; Equivocal: 5-10 IU/mL	CLIA	5 ml Plain	2
RM	Rubella IgM	Negative:<0.8, Positive:>1.0	ECLIA	5 ml Plain	5
SARS2AB	SARS-CoV-2 Antibodies IgM & IgG (by Rapid Test)	Non-Reactive	RTK	5 ml Plain	Call
SC2GS	SARS-CoV-2 S Antibody IgG (by CLIA) – antibodies against receptor binding domain (RBD) of viral spike (S) protein, which may be more likely to confer immunity.	Non Reactive: < 50AU/ml (x 0.142 = BAU/mL)	CLIA	5 ml Plain / 3ml EDTA (plasma)	3-5
SARS2AG	SARS-CoV-2 Antigen (by Rapid Test)	Non-Reactive	RTK	Nasopharyngeal Swab in Plain tube	Call
SEMA	Seminal Analysis	-	WHO guidelines	Call lab / patient to lab <i>Pre-appointment, specimen must reach lab within 1 hr (State time of collection).</i>	1
SRT	Serotonin			5 ml Plain	Research, call
SHBG	Sex Hormone Binding Globulin (SHBG)	nmol/L Males: 13.3-89.5 Females (20-46 yrs): 18.2-135.5 Females (47-91 yrs) (Post-menopausal): 16.8-125.2	CLIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	7
SPV	Spermatozoa for Post-vasectomy		Post-Vasectomy Semen Analysis	Call lab / patient to lab <i>Specimen must reach lab in 2 hours.</i>	1
SMAG	Spinal Muscular Atrophy (SMA) Genetic Assay	Refer to lab report	PCR	3 ml EDTA	7-10
SCC	Squamous Cell Carcinoma Ag (SCC Ag/ TA-4)	<2.7ng/mL	CLIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin</i>	5

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
				<i>B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	
STOA	Stone (Calculi) Analysis	-	FTIR	Kidney/Biliary Stone	14-21
STBD	Streptococcus Group B DNA Detection	Not Detected	PCR	Swab/ 3ml Blood	5-7
SYFEM	Synovial Fluid FEME - Cell count, Gram's stain, protein & crystals	Based on report	-	Synovial Aspirate	2
FTES1	Testosterone, Free	M: 0.17 - 0.66 nmol/L F : 0.006 - 0.055 nmol/L (Non-,menopausal) F : 0.002 - 0.033 nmol/L (Post menopausal)		5 ml Plain	7
TES	Testosterone, Total	Male: 5.57 - 24.84 nmol/L Female: < 0.32 - 2.39 nmol/L	CLIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	5
THLDA	Thalassaemia Alpha only DNA Analysis (7 mutations)		PCR	3 ml Whole/ Cord Blood in EDTA or 10 ml Amniotic Fluid, <i>Avoid contamination from mother's blood.</i>	14
THLDB	Thalassaemia Beta only DNA Analysis (22 mutations)		PCR	3 ml Whole/ Cord Blood in EDTA or 10 ml Amniotic Fluid, <i>Avoid contamination from mother's blood</i>	14
THLD1	Thalassaemia Alpha & Beta DNA Analysis (adult)		PCR	3 ml Whole/ Cord Blood in EDTA or 10 ml Amniotic Fluid, <i>Avoid contamination from mother's blood)</i>	14
THLD2	Thalassaemia Alpha & Beta DNA Analysis (prenatal/neonate)		PCR	3 ml Whole/ Cord Blood in EDTA or 10 ml Amniotic Fluid, <i>Avoid contamination from mother's blood</i>	14

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
THG	Thyroglobulin	3.50-77.00 ng/mL	ECLIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	10
TBG	Thyroid Binding Globulin (TBG)			5 ml Plain	Research, call
TSH	Thyroid Stimulating Hormone (TSH)	mIU/L 0 day (Cord Blood) <20.00 4-6 day <6.00 7day - <6M 0.73 – 4.77 6m – 13Y 0.70 – 4.17 14 – 18Y 0.47 – 3.41 ≥ 19Y 0.35 – 4.94	CLIA	5 ml Plain	1
TSHR	TSH Receptor Antibody	<15.00%	RIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	7
FT4	Thyroxine, Free (FT4)	pmol/L 0 Day (Cord blood) >15.00 4 - 6 days 12.00 - 18.80 7 days - < 1 year 10.50 - 18.80 1 - 18Y 9.98 – 14.29 ≥ 19Y 9.10 – 19.05	CMIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	1
TPA	Tissue Polypeptide Ag (TPA) (non-specific tumour marker)	<75.00 U/L	CLIA	5 ml Plain	7-10
TOXG	Toxoplasma IgG	Negative:<1.0, Grey zone: 1.0 - < 3.0, Positive:≥3.0	ECLIA	5 ml Plain	5
TOXM	Toxoplasma IgM	Negative:<0.8, Grey zone: 0.8 - <1.0, Positive: ≥1.0 index	ECLIA	5 ml Plain	5

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
TOXD	Toxoplasma gondii DNA	Not Detected	PCR	5 ml umol/L Plain/ CSF/ Amniotic Fluid	5-7
TPHA	Treponema Pallidum Hemagglutination Assay	Non-Reactive	Hemagglutination	5 ml Plain	1
TRA	Transferrin (suggest Iron Status Evaluation profil)	2.0 – 3.6 umol/L	Immune-turbidmetric	5 ml Plain, <i>Fasting sample.</i>	3
	Transforming Growth Factor Beta-1 (TGF β-1)				Research, call
TPD	Treponema pallidum DNA (by PCR)	Not Detected	PCR	Swab / CSF	7
TPAB	Treponema pallidum Ab (TP-Ab)	Non-Reactive	CLIA	5 ml Plain	3
FTAM	Treponema, FTA-Abs IgM	Negative	FIA	5 ml Plain	10
FTAG	Treponema, FTA-Abs total (IgG)	Negative	FIA	5 ml Plain	10
RPR	Rapid Plasma Reagin RPR, Non-treponemal Test	Non-Reactive	Agglutination	5 ml Plain	1
TVD	Trichomonas vaginalis DNA (by PCR)	Not-Detected	PCR	Genital Swab / FVU	7
TG	Triglycerides	mmol/L Fasting <1.70 ; Non-fasting <2.00	Enzymatic, End Point	5 ml Plain, <i>Fasting sample.</i>	1
FT3	Triiodothyronine, Free (FT3)	pmol/L 4 D - < 1Y 3.56 – 7.48 1 Y – 11 Y 4.29 – 6.79 12 Y – 14 Y 3.84 – 6.06(M) 4.44 – 6.65(F) 15 Y – 18 Y 3.55 – 5.70(M) 3.46 - 5.92(F) ≥ 19 Y 2.30 - 6.30	CMIA	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample.</i>	2
TNIH	Troponin I, High Sensitive Quantitative (hsTnI)	M: <19.8pg/mL F: <11.6 pg/mL	LIA	5 ml Plain	3
TRI	Troponin I (cTnI), Rapid Qualitative	Negative	RTK	5 ml Plain	1
TNFA	Tumour Necrosis Factor-Alpha (TNF-α)	< 8.1 pg/mL	CLIA	5 ml Plain	Research, call
UREA	Urea	2.8-7.2	Urease	5 ml Plain	1

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
UUREA	Urea, Urine	7-16 g/24 hrs	Urease GLDH	24 hr Urine, <i>in Refrigeration without acid preservative</i>	3
URPD	<i>Ureaplasma spp.</i> DNA Detection	Not Detected	PCR	Swab	5-7
UA	Uric Acid	Male: 208.3-428.4umol/L Female:154.7- 357umol/L	Uricase	5 ml Plain	1
UUA	Uric Acid, Urine	M:250-800 mg/ 24hrs; F:250-750 mg/ 24hrs;	Uricase	24 hr Urine, <i>in Refrigeration without acid preservative</i>	3
UFEM	Urine FEME / Urinalysis - 10 chemical parameters & microscopic examination	Negative /Normal	Full examination analysis	20 ml mid stream urine	1
UPT	Urine Pregnancy Test (Urine β-hCG), rapid	Negative	RTK	20 ml Urine	1
VMA	Vanillylmandelic Acid (VMA)	1.0-7.5 mg/day	HPLC	24 hr Urine, <i>in Acid preservative and Refrigeration</i>	7
VMAR	Vanillylmandelic Acid (VMA)/Creatinine Ratio		Calculation	20 ml Urine (random)	7
VZG	Varicella-zoster IgG (Chicken Pox)	<150(-) mIU/mL	CLIA	5 ml Plain	8
VZM	Varicella-zoster IgM (Chicken Pox)	Index Negative:<0.8, Equivocal 0.8 to <1.1 Positive: $\geq$ 1.1	ELISA	5 ml Plain	12
VZD	Varicella-zoster Virus (VZV) DNA (by PCR)	Not detected	PCR	Swab / Urine / CSF / Serum	7
	Vascular Endothelial Growth Factor (VEGF)				Research, call
VA	Vitamin A (Retinol)	0.3-0.7 mg/L	HPLC	5 ml Plain <i>Interference possible in patients treated with biotin (vitamin B7, B8 or H) or taking any food supplement containing biotin. Essential to stop treatment 8 days before taking the sample. Wrap specimen to avoid light.</i>	7-10
VB12	Vitamin B12 (Cobalamin)	180-914 pg/ml	CLIA	5 ml Plain, <i>Separate serum & refrigerate a.s.a.p.</i>	5-7

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
VDT	Vitamin D, Total (25-OH D2 & D3)	ng/ml Deficient: < 20 Insufficient: 20 to 29 Sufficient: 30-100 Exceed Safety Limit: > 100	CLIA		
WEIL	Weil-Felix Tests (<i>Rickettsia</i> Ab /Typhus)	Non-Reactive	Agglutination	5 ml Plain	1
WET	Wet Mount Examination (refer to <i>Trichomonas</i>)	Negative	Direct smear	Vaginal Swab in medium	1
WWF	Widal & Weil-Felix Tests (WWF)	Non-Reactive	Agglutination	5 ml Plain	1
WT	Widal Tests (<i>Salmonella</i> Ab/Typhoid)	Non-Reactive	Agglutination	5 ml Plain	1
ZIKAR	Zika Virus RNA	Not Detected	PCR	5 ml Plain/ Urine/ CSF	7-10
	<i>Abused Drug tests SCREENING ASSAYS (Qualitative / Quantitative)</i>				
AMPH	Amphetamines, by EIA	Negative (Cut-off:1000 ng/mL)	EIA	20 ml Urine	2
AMPHR	Amphetamines, Rapid Screen	Negative	RTK	20 ml Urine	1
BARU	Barbiturates	Negative:<200ng/mL	Enzyme Multiple Immunoassay Test	20 ml Urine	6
BENU	Benzodiazepine	< 200 ng/ml	EIA	20 ml Urine	6
CANN	Cannabinoids (THC), by EIA	Negative	EIA	20 ml Urine	2
CANR	Cannabinoids (THC), Rapid Screen	Negative	RTK	20 ml Urine	1
COCU	Cocaine	Negative:<200ng/mL	Enzyme Multiple Immunoassay Test	20 ml Urine	6

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
NICOT	Cotinin (Nicotine metabolite)	Negative: <0.5ug/mL	Enzymeimmuno assay, Microgenics	20 ml Urine	7
ETH	Ethanol (Ethyl Alcohol)	<30.0, toxic : ≥ 100	Enzymatic reaction	5 ml Plain	5
UHER	Heroin	Cut-off: 300 ng/mL	Homogeneous enzyme immunoassay	20 ml Urine	5
KETA	Ketamine	Negative	Competitive Immunoassay	20 ml Urine	5
MTET	Methanol & Ethanol (by LC-MS)	Negative	LC-MS	20 ml Urine	7-12
METHR	Methamphetamines, Rapid Screen	Negative	RTK	20 ml Urine	1
MORP	Morphine/Opiates, By EIA	Negative	EIA	20 ml Urine	2
MORR	Morphine/Opiates, Rapid Screen	Negative	RTK	20 ml Urine	1
METD	Methadone, Quantitative	Negative	RTK	20 ml Urine	6
	Therapeutic Drug Assays				
ACET	Acetaminophen / Paracetamol	Therapeutic: 10.0-20.0 µg/mL Toxic: >150.0 µg/mL	Enzymatic/Color (Hydrolysis)	5 ml Plain	5
AMIK	Amikacin	µg/mL Trough Therapeutic :1.0-4.0 Trough : 5.0-8.0 Peak Therapeutic : 20.0-25.0 Peak : 25.0-30.0 Toxic : > 35.0	Enzyme Multiple Immunoassay Test (EMIT)	5 ml Plain	5
CARB	Carbamazepine (Tegretol)	4-12 ug/mL; Toxic: >12 ug/mL	Enzymatic/Color (Hydrolysis)	5 ml Plain	5
CCSA	Cyclosporin A	100-400 ng/mL	Nephelometry	3 ml EDTA Plasma	5
DIG	Digoxin (Lanoxin)	Adult: 1.0-2.0 ng/mL ; children: 1.1-1.7 ng/mL ; Toxic: >2.0 ng/mL	CLIA	5 ml Plain	5
FK506	FK506 (Tacrolimus)	5.0-20.0 ng/mL	Particle Enhanced Turbidimetric Inhibition	3 ml EDTA	5

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
			Immunoassay (PETINIA)		
GENT	Gentamycin	4.0-10.0 µg /mL at peak Trough: <2.0 µg/mL	Particle Enhanced Turbidimetric Inhibition Immunoassay (PETINIA)	5 ml Plain	5
LIT	Lithium	Normal : <1.5mmol/L Toxic : > 2.5 mmol/L	Colorimetric/Endpoint	5 ml Plain	5
MTT	Methotrexate (MTX)	Toxic: 24hr >10 umol/L 48hr >1.0 umol/L 72hr >0.1 umol/L	CLIA	5 ml Plain	5
PNB	Phenobarbital (Luminal)	10-40 ug/mL	Homogeneous enzyme immunoassay	5 ml Plain	5
PNT	Phenytoin (Dilantin)	10-20 ug/mL; Toxic: >20 ug/mL	Homogeneous enzyme immunoassay	5 ml Plain	5
SIRO	Sirolimus (Rapamycin)	Sirolimus Treatment: Trough: 2 mg/day treatment: 4.5 - 14 ng/ml Trough: 5 mg/day treatment: 10 - 28 ng/mL Sirolimus and Cyclosporine Treatment: Trough: 6.3 - 16.0 ng/mL Cyclosporine Withdrawal: Trough: 17.0 - 29.0 ng/mL	Chemiluminescent Microparticle ImmunoAssay	3 ml EDTA	7
TPL	Theophylline (Aminophylline)	10-20 ug/mL; Toxic: >20 ug/mL	Homogeneous enzyme immunoassay	5 ml Plain	5
VALA	Valproic Acid (Depakine)	50-100 ug/mL; Toxic: >100 ug/mL	Homogeneous enzyme immunoassay	5 ml Plain	5

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
VANC	Vancomycin	Trough: 5-10 ug/mL; Toxic ; Trough: >10 ug/mL Peak: 20-40 ug/mL; Toxic ; Peak: >40 ug/mL	Homogeneous enzyme immunoassay	5 ml Plain	5
	Chemical Hazards				
ACETU	Acetone, Urine	<25 PPM	HS-GCMS	20 ml Urine	7-14
CHL1	Cholinesterase, RBC (long term exposure to Pesticides)	20-72 uM/sec/L of W.B.	Enzyme substrate	3 ml EDTA/Heparin	7-14
CHL	Cholinesterase, Serum (acute exposure to Pesticides)	M: 4.62-11.50 KU/L F: 3.93-10.80 KU/L	Butyrylthiocholine	5 ml Plain	3
CYANU	Cyanide, Urine (may consider plasma Lactate)			20 ml Urine	7-14
SPMA	Benzene (as S-Phenylmercapturic Acid SPMA in Urine)	<25 µg/g creatinine	LCMS	20 ml Urine	7-14
BENZ	Benzene (as Phenol in Urine)	< 50 µg/g creatinine	HPLC	20 ml Urine	7-14
FORMU	Formaldehyde, Urine	50 ppb	In House HS-GCMS Method	20 ml Urine	7-14
MEKU	Methyl Ethyl Ketone (MEK) in Urine	17 mg/dL, 100 ppb, 60.6 µg/g creatinine	In House Method based on QWI OG17-93	20 ml Urine	7-14
HEX	n-Hexane (as 2,5-Hexanedione in Urine)	<0.5 mg/L <0.303 mg/g creat	GCFID	20 ml Urine	7-14
PRQ	Paraquat, Serum	<0.1 ppm	Colorimetric method		7-10
PRQU	Paraquat, Urine	<5 ppm	Colorimetric method	20 ml Urine	7-10
STYRU	Styrene (as Mandelic Acid in Urine)	17 mg/dL, 10 µg/L, 6.06 µg/g creatinine	In House HS-GCMS Method	20 ml Urine	7-14

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
TOLU	Toluene (as Hippuric Acid in Urine)	17 mg/dL, 0.5 ppm, 0.005 g/g creatinine	In House Method based on QWI CH17-127	20 ml Urine	7-14
TCA	Trichloroethylene (as Trichloroacetic Acid in Urine)	17 mg/dL, 10 mg/L	In-House Method	20 ml Urine	7-14
XYL	Xylene (as Methylhippuric Acid), Urine	1.5 g/g creatinine	NIOSH 8301	20 ml Urine	7-14
	Trace & Toxic Elements				
ALU	Aluminium (Al), Blood	< 5.9 ug/L	ICP-MS	5 ml TET Heparin	7-10
ALUU	Aluminium (Al), Urine	<50 ug/g cre	LC-MS/MS	10 ml Urine	7-14
ARS	Arsenic (As), Blood	Not Detected (<0.06)	ICP-MS	5 ml EDTA	14-20
ARSU	Arsenic (As), Urine	<77.8 ug/g cre	ICP-MS	10 ml Urine	14-20
ARSU2	Arsenic (AS), Inorganic in Urine	<77.8 ug/g cre	LC-MS/MS	10 ml Urine	7-14
CADM	Cadmium (Cd), Blood	<5 ug/L	ICP-MS	5 ml EDTA	7-14
CADMU	Cadmium (Cd), Urine	<5 ug/g cre	LC-MS/MS	10 ml Urine	7-14
CHRB	Chromium (Cr), Blood	<1.2 ug/L	ICP-MS	5 ml EDTA	7-14
CHRU	Chromium (Cr), Urine	<55.6 ug/g cre	LC-MS/MS	10 ml Urine	7-14
COBB	Cobalt (Co), Blood		ICP-MS	5 ml EDTA	7-14
COBU	Cobalt (Co), Urine		LC-MS/MS	10 ml Urine	7-14
COP	Copper (Cu), Serum	700-1500 ug/L	Atomic Absorption	5 ml TET Heparin	7-14
COPU	Copper (Cu), Urine	24Hr: <60 ug ; Random: <80 ug/dL	LC-MS/MS	10 ml Urine	7-14
PB	Lead (Pb), Blood	<50ug/dl	ICP-MS	5 ml EDTA	7-10
UPB	Lead (Pb), Urine	<5 ug/g cre	LC-MS/MS	10 ml Urine	7-10
MNBL	Manganese (Mn), Blood	129 -189 umol/L	ICP-MS	5 ml EDTA	7-14
MNU	Manganese (Mn), Urine	<19 ng/l	AAS	10 ml Urine	7-14
HG	Mercury (Hg), Blood	<74.8 nmol/L	LC-MS/MS	5 ml EDTA	7-14
UHG	Mercury (Hg), Urine	<20 ug/g cre	ICP-MS	10 ml Urine	7-14
NIBL	Nickel (Ni), Blood	0.34 -1.4 ug/dl	ICP-MS	5 ml EDTA	7-14
NIU	Nickel (Ni), Urine	<18.2 ug/g creatinine	ICP-MS	10 ml Urine in TET Plain	7-14
ZN	Zinc (Zn), Serum	700-1200 ug/L	Atomic Absorption	5 ml TET Heparin	7-14

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
ZNU	Zinc (Zn), Urine	15-120 ug/dL	ICP-MS	10 ml Urine	7-14
	Cytopathology				
PAP	PAP Smear	-	Papanicolaou staining method	Fixed smear	4-6
PALP	PAP Test, Liquid-based preparation			Cervical brush in collection kit	4-6
CY04	Smear - sputum, brushing etc.			Fixed smear	5-7
CY05	Fluid - urine, washing, secretion, body fluid etc			In Sterile Container	5-7
CY06	Fine Needle Aspirate Cytology			Relevant fixed smears	5-7
HP01	Small Specimen/Biopsy (<3cm) - Endometrial curettings, Appendix, Fallopian tubes, Gall bladder, Vas deferens, Lymph nodes, Skin biopsies, Prostatic biopsies, single Ovary, single Tonsil, Cervical punch/ Colposcopic biopsies, Gastro-intestinal tract biopsies.			10% buffered formalin fixed tissue Specimen must be accompanied with appropriate and relevant clinical data. The specimen container must be labelled with patient's identification and anatomic site of the sample.	5-7
HP02	Medium Specimen (<6cm) - Prostatic chips (TURP), Cervical Cone biopsies, Simple Mastectomy, Uterus (without ovaries), Brest Lump, Lumps etc			10% buffered formalin fixed tissue Specimen must be accompanied with appropriate and relevant clinical data. The specimen container must be labelled with patient's identification and anatomic site of the sample.	5-7
HP03	Large Specimen (>6 cm) - Bladder, Breast Mastectomy, Caecum, Cervical Cone Biopsy, Colectomy, Gastrectomy,			10% buffered formalin fixed tissue Specimen must be accompanied with appropriate and relevant clinical data. The specimen container must be labelled	7-10

Code	Name of Test	Reference range	Methodology	Type of Specimen	TAT (Days)
	Intestine, Kidney, Liver, Uterus with tubes & ovaries, etc			with patient's identification and anatomic site of the sample.	
HP04	Large Complex/Radical Specimen Contact the lab for specific charges - Wertheim's hysterectomy, TAHBSO with entire cervix, etc			10% buffered formalin fixed tissue Specimen must be accompanied with appropriate and relevant clinical data. The specimen container must be labelled with patient's identification and anatomic site of the sample.	CALL
	Immunohistochemistry (IHC) & Special Stains			Contact us for more information on stains available and charges.	CALL

Remarks:

RIA	-	Radioimmunoassay
ICP-MS	-	Inductively Coupled Plasma – Mass Spectrometry
HPLC	-	High-Performance Liquid Chromatography
CLIA	-	Chemiluminescent Immunoassay
ELISA	-	Enzyme-Linked Immunosorbent Assay
FLISA	-	Fluorescent-linked Immunosorbent Assay
ECLIA	-	ElectroChemiLuminescence ImmunoAssay
RTK	-	Rapid test kit
CLEIA	-	Chemiluminescent Enzyme ImmunoAssay
SRID	-	Single Radial Immunodiffusion
PCR	-	Polymerase Chain Reaction
EIA	-	Enzyme ImmunoAssay
LC-MS	-	Liquid Chromatography – Mass Spectrometry
ICP-MS	-	Inductively Coupled Plasma – Mass Spectrometry
AAS	-	Atomic Absorption Spectrosc